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ABSTRACT 
 
 
Angelman syndrome (AS) is a rare genetic and neurological disorder presenting with 
severe developmental delay, ataxia, epilepsy, and lack of speech. AS is associated with a neuron-
specific loss of function of the maternal UBE3A allele, a gene encoding an E3 ubiquitin ligase. 
Currently, no cure exists for this disorder; however, recent research using an AS mouse model 
suggests that pharmacological intervention is plausible, and can alleviate some of the detrimental 
phenotypes reported in AS patients. 
Although there is no curative treatment for AS, seizure medication and behavioral therapies 
are most commonly prescribed in order to minimize symptoms. However, these options only 
moderately improve quality of life and can cause adverse side effects, such as alterations in mood 
and cognition following seizure treatment. Unfortunately, epilepsy is a common cause of death in 
AS and affects greater than 80% of AS patients, with 77% of those patients remaining refractory. 
The severity of seizures and lack of consistently effective anti-epileptic medications for AS 
patients demonstrates a considerable need for other therapeutic options. The goal of this work was 
to evaluate the effects of seizure therapies that have proven beneficial for treating refractory 
epilepsy in seizure-related disorders. These studies focused specifically on advances in both a 
pharmacological and dietary therapy evaluated in the AS mouse model.  
Previous work in our lab has demonstrated the importance of interneurons and GABAergic 
tone in hippocampal network regulation and cognition. GABA is an important modulator of 
synaptic plasticity, and learning increases both inhibitory synaptogenesis and GABA release from 
 ix 
 
hippocampal inhibitory neurons. A neuronal excitatory/inhibitory imbalance, coupled with 
decreased GABAergic tone, altered synaptic plasticity, and impaired cognition have been reported 
in the AS mouse model. Therefore, we proposed to examine two therapeutic strategies used in 
seizure treatment – a ketone ester (KE) supplement, which is thought to increase the 
[GABA]/[glutamate] ratio via alterations in brain metabolism, and ganaxolone, a positive allosteric 
modulator of GABAA receptors. We evaluated the effects of each therapeutic on learning and 
cognitive enhancement, alterations in synaptic function, and anticonvulsant activity. We 
hypothesized that both the KE and ganaxolone would demonstrate anticonvulsant efficacy in both 
behavioral and chemiconvulsant seizure models. Additionally, as chronic epilepsy has been linked 
to progressive cognitive and memory impairment which may be related to GABA deficiencies, we 
hypothesized that both therapeutics would improve cognition and modulate synaptic plasticity 
(i.e., synaptic function).  
KE administration produced sustained ketosis and improved motor coordination, learning 
and memory, and synaptic plasticity in AS mice. The KE was also anticonvulsant and altered brain 
amino acid metabolism in AS treated animals. Ganaxolone was anxiolytic, anticonvulsant, and 
improved motor deficits in AS mice. Four weeks of treatment also led to recovery of spatial 
working memory and hippocampal synaptic plasticity deficits. This study demonstrates that the 
KE and ganaxolone ameliorate many of the behavioral abnormalities in the adult AS mouse, 
possibly through modulations of GABAergic tone. These results support clinical investigation of 
both the KE and ganaxolone in AS, which may lead to the development of a novel treatment for 
AS patients.
 1 
 
  
 
 
 
 
CHAPTER ONE: 
 
 LITERATURE REVIEW1 
 
Angelman Syndrome 
Angelman syndrome (AS) is a rare neurological disorder with a prevalence of 1 in 10,000-
20,000 individuals. It is characterized by an overall happy demeanor, severe developmental delay, 
frequent smiling and laughter, abnormal gait, speech impairments, and epilepsy (Clayton-Smith 
and Laan, 2003; Williams et al., 2010). Although AS was first described in 1965, it wasn’t until 
the 1980s that chromosomal region 15q11.2-13 was recognized to be associated with the disorder. 
Ube3a, an E3 ubiquitin ligase, was subsequently identified as the critical gene responsible for AS 
(Kishino et al., 1997; Matsuura et al., 1997). Ube3a undergoes epigenetic neuron-specific 
imprinting, a phenomenon that occurs in a parent-of-origin-dependent manner, and in which the 
methylation pattern on the paternal allele leads to paternal Ube3a silencing. With paternal Ube3a 
silenced, any disruption in maternal Ube3a results in the AS phenotype. These genetic 
abnormalities include small or large deletions of chromosome 15 (~75% of cases), UBE3A 
mutations (~5-10%), uniparental paternal disomy (~1-2%), and imprinting center defects (~3%). 
The remaining cases (~10-15%) are idiopathic and have no identifiable genetic abnormality in the 
15q11.2-13 region, yet still meet the diagnostic criteria for AS (Clayton-Smith and Laan, 2003; 
Williams et al., 2010; Buiting et al., 2014). In most instances the genetic anomalies are sporadic, 
                                                 
1 Portions of this chapter have been previously published in Expert Opinion on Orphan Drugs, 2016, 4(3): 317-325, 
and have been reproduced with permission from Taylor & Francis. See Appendix B. 
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although familial recurrence is reported in an estimated seven percent of AS cases (Moncla et al., 
1999). Despite the severity of the disorder and deficiency of treatment options, recent research 
using an AS mouse model suggests that therapeutic intervention is plausible, and can alleviate 
some of the detrimental phenotypes seen in AS patients.  
 
An AS Null-Mutation Mouse Model 
Following the identification of AS as a monogenic disorder in humans, a transgenic mouse 
model was created by introducing a null mutation in the maternal Ube3a gene. Jiang et al. (1998) 
prepared a targeting vector to replace 3kb of genomic DNA containing exon 2, including a portion 
of the Ube3a initiation codon. This deletion created a frameshift mutation and inactivated all 
Ube3a isoforms. This well-characterized Ube3a maternal deficient (m-/p+) mouse model 
recapitulates many aspects of the human AS phenotype, demonstrating motor dysfunction 
manifested as a shorter latency to fall from the accelerating rotarod, inducible audiogenic seizures, 
context-dependent learning deficits, and severely impaired synaptic plasticity as measured by 
alterations in hippocampal long-term potentiation (LTP). In addition, the AS mouse showed 
paternal silencing that was eventually found throughout the CNS (Gustin et al., 2010; Daily et al., 
2012).  
The Ube3a m-/p+ mouse model was originally produced and is commonly maintained on 
the 129/SvEv background. This was expanded in many studies to the C57BL/6 background due to 
the historic use of C57BL/6 in behavioral analysis (Abeliovich et al., 1993; Bach et al., 1995; 
Crawley et al., 1997). Mice on the C57BL/6 background are well-characterized in behavioral 
testing focused on learning and memory and exhibit abnormal epileptiform activity, but do not 
display the tonic-clonic audiogenic seizure phenotype observed in the 129/SvEv strain. Many 
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researchers have relied on using a hybrid background by breeding 129/SvEv m+/p- females and 
C57BL/6 m+/p+ males to create a maternal deficient F1 strain. Hybrid mice also demonstrate some 
of the behavioral phenotypes seen in humans, including enhanced propensity to seizure, albeit to 
a lesser degree than mice on the pure 129/SvEv background (Jiang et al., 1998). 
The utility of the null mutation Ube3a maternal deficient mouse model is evident in our 
current understanding of the mechanisms of Ube3a silencing, targets of Ube3a, and alterations in 
synaptic structure and biochemistry. Beyond these discoveries is the mouse model’s capacity as a 
mode for testing therapeutic strategies, specifically with a focus on the four major phenotypes of 
the mouse model that are also prevalent in the human condition. These include the motor 
coordination and balance deficiencies, cognitive disruption, and increased seizure propensity. 
Furthermore, there is a strong defect in synaptic plasticity across Schaffer collateral synapses of 
the hippocampal area CA1. The current study focuses on therapeutic interventions related to these 
four major areas of dysfunction in the AS mouse model, utilizing both the pure 129/SvEv and 
C57BL/6 strains in order to examine each of these phenotypic deficits. 
 
Seizure Susceptibility and EEG Patterns 
An estimated 80% of AS individuals have epilepsy, and intractable epilepsy has been 
reported as a primary reason for patient hospitalization (Valente et al., 2006; Pelc et al., 2008; 
Thibert et al., 2009; Williams et al., 2010). AS patients are commonly diagnosed with medically 
refractory epilepsy, as they often display epileptic seizures that are resistant to common anti-
epileptic drugs (AEDs). Studies have demonstrated increased seizure susceptibility in AS deletion 
patients, as these deletions also typically involve the non-imprinted GABAA α5, β3, and γ3 subunit 
genes, resulting in patients hemizygous for these genes (Minassian et al., 1998). Seizure onset in 
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AS patients generally occurs between ages 1 and 3, and reports include both generalized and partial 
seizures. The most frequently observed seizure types described in AS include infantile spasms, 
myoclonic seizures, and atypical absence seizures, although both tonic and tonic-clonic seizures 
have been documented (Valente et al., 2006; Pelc et al., 2008; Thibert et al., 2009).  
Commonly prescribed AEDs often have limited success in AS, and many of these 
medications can have side effects that alter cognition (Drane and Meador, 1996; Campos-Castello, 
2006; Mula and Trimble, 2009). Furthermore, chronic, intractable epilepsy has been linked to 
progressive memory impairment (Helmstaedter et al., 2003). It has also been suggested that 
chronic epilepsy may negatively affect memory, cognition, and can cause extensive hippocampal 
damage following various types of seizure episodes (Sutula et al., 1995; Hermann et al., 2002; 
Aldenkamp and Arends, 2004). Seizures are one of the most devastating aspects of this disorder; 
hence, it is crucial to discover or develop novel therapeutics to treat this devastating phenotype. 
Abnormal EEG recordings in AS patients are extremely common, with three predominant 
EEG patterns described: 1) persistent rhythmic 4-6 Hz generalized activity, not associated with 
drowsiness and persisting throughout most of the EEG recording, even during eye closure, 2) 2-3 
Hz rhythmic delta activity prominent in the anterior regions with superimposed interictal 
epileptiform discharges in the form of spikes and sharp waves, and 3) spikes and sharp waves 
mixed with 3-4 Hz components of high amplitude, located mainly posteriorly, and facilitated by 
eye closure. Observation of these abnormal patterns during an EEG, particularly the commonly-
recognized delta activity during the awake state, often aid in the diagnosis of AS prior to genetic 
testing (Laan et al., 1997). 
Persisting abnormal EEG patterns are also recorded in Ube3a m-/p+ mice, and include 
bilateral 3 sec spike-wave activity intermixed with polyspikes and spike-wave discharges (SWDs) 
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(Jiang et al., 1998). Longer episodes of epileptiform activity are accompanied by behavioral 
immobility, a common characteristic of absence seizures. Similarly, in an AS mouse model 
targeting Ube3a inactivation using a lacZ reporter, EEGs demonstrated 4-5 Hz SWDs lasting 5-12 
seconds (Miura et al., 2002). The SWDs occurred at variable frequencies, but consistently 
appeared in the recording every 2-3 minutes. These mice were also administered valproate and 
ethosuximide to reduce seizure frequency, resulting in reduced SWDs. 
 
Targeted Therapeutics and the GABAergic System 
Previous work has focused on a variety of therapeutic strategies for AS, including genetic 
intervention and alterations (Van Woerden et al., 2007; Kaphzan et al., 2013), modulation of 
synaptic plasticity and related signaling pathways (Baudry et al., 2012; Kaphzan et al., 2012; Cao 
et al., 2013; Hethorn et al., 2015; Sun et al., 2016), Ube3a gene replacement therapy (Daily et al., 
2011), and more recently, targeted therapeutics. Many of these targeted therapeutics emphasize 
the importance of paternal Ube3a activation. The first breakthrough in this work demonstrated that 
the topoisomerase inhibitor topotecan increases paternal Ube3a expression throughout the mouse 
CNS for at least 12 weeks following cessation of drug delivery (Huang et al., 2012). While 
topotecan is an FDA-approved drug used for multiple types of cancer treatments, the toxicity, lack 
of specificity, and its ability to alter expression of multiple genes makes this an unlikely 
therapeutic. Moreover, this mechanism of paternal Ube3a unsilencing also reduces expression of 
paternal non-coding RNAs associated with Prader-Willi syndrome, and could potentially produce 
off-target Prader-Willi-like effects. Antisense therapy using antisense oligonucleotides (ASOs) is 
another form of gene-specific therapy that can achieve specific reduction of the paternal non-
coding antisense transcript (Ube3a-ATS) and restore paternal Ube3a expression in AS. A single 
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administration of ASOs specific to the Ube3a-ATS increased paternal Ube3a expression for four 
months (Meng et al., 2015). Other studies have utilized targeted therapeutics in order to enhance 
mitochondrial antioxidant capacity (Llewellyn et al., 2015; Santini et al., 2015), while others have 
focused on the GABAergic system (Egawa et al., 2012), as significant alterations in GABAergic 
tone have been reported in the AS mouse brain and may affect many of the phenotypes observed 
in AS. 
Decreased neuronal inhibition has been reported in both human and mouse AS brains. In a 
case study of a 21-year-old AS patient, post-mortem neurochemical studies demonstrated a 
significant reduction of the primary inhibitory neurotransmitter γ-aminobutyric acid (GABA) in 
cerebellar cortex tissue, and elevated glutamate levels in the frontal and occipital cortices (Jay et 
al., 1991). Additionally, non-imprinted GABRB3 expression and β3/β2 and α5/α1 GABAA subunit 
expression ratios in the human AS cortex are significantly decreased compared to age-matched 
controls, indicating impaired extrasynaptic and intact synaptic GABAergic inhibition (Samaco et 
al., 2005; Roden et al., 2010). These reports suggest decreased neuronal inhibition by GABAA 
α5β3γ2 receptors and unchanged/increased cortical excitation via α1β2γ2 receptors (Roden et al., 
2010). The resulting excitatory and inhibitory imbalance in the AS brain may contribute to the 
epileptic and cognitive phenotypes of the disorder. In vivo cerebellar activity recordings were also 
performed in Ube3a m-/p+ mice, and ~160 Hz fast oscillations were measured (Chéron et al., 
2005). These oscillations were coupled with increased Purkinje cell firing rates, which may 
specifically contribute to the ataxic phenotype observed in AS and indicate a cerebellar inhibitory 
imbalance. Moreover, tonic inhibition is decreased in cerebellar granule cells and direct Ube3a 
target GAT1, a GABA transporter that removes GABA from the synaptic cleft, is increased in the 
mouse cerebellum (Egawa et al., 2012). There is also a significant decrease in inhibitory drive onto 
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neocortical L2/L3 pyramidal neurons following the loss of excitatory inputs (Wallace et al., 2012). 
This overall CNS excitatory/inhibitory imbalance could affect detection or integration of sensory 
information by decreasing the signal-to-noise ratio in certain areas of the brain. Therefore, a 
targeted therapeutic that increases tonic inhibition may alter this ratio and lead to improved 
information processing and decreased seizure propensity in AS patients.  Potential treatments may 
be in the form of GABA agonists, positive allosteric modulators of GABA receptors, or any 
therapeutic that dampens excitability, enhances GABAergic signaling, or increases tonic 
inhibition. 
Defective GABAergic signaling and increased excitability in the AS brain not only affects 
sensory and information processing and ataxia, but likely has a significant impact on seizure 
propensity. A significant population of AS individuals have epilepsy that frequently involves many 
seizure types, and 84% of AS deletion patients have documented refractory epilepsy (Valente et 
al., 2006; Pelc et al., 2008; Thibert et al., 2009). As previously mentioned, AS patients with 
chromosomal deletions generally demonstrate enhanced propensity to seizure, and these deletions 
typically involve the non-imprinted genes encoding the GABAA receptor, including GABRB3 
(Egawa et al., 2008). GABRB3 encodes for the β3 subunit, which is an essential component of 
extrasynaptic GABAA receptors in various brain regions, particularly during development (Nusser 
et al., 1998). A deletion of GABRB3 results in cortical hyperexcitability and increased 
susceptibility to seizure activity, and the resulting GABAergic dysfunction is expected to cause 
significant alterations in brain function (Vicini and Ortinski, 2004). Seizure severity and a lack of 
consistently effective anti-epileptic medications for AS patients indicates an imminent need for 
alternative therapeutics that enhance tonic inhibition or decrease excitation. 
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Administration of 4,5,6,7-tetrahydroisothiazolo-[5,4-c]pyridine-3-ol (THIP), a selective 
extrasynaptic GABAA receptor agonist, partially rescued cerebellar dysfunction in the AS mouse 
model by improving various gait and ataxic parameters (Egawa et al., 2012). Moreover, it has been 
suggested that a hippocampal excitatory/inhibitory balance is critical for proper learning, and that 
hilar GABAergic inhibitory interneurons play an important role in spatial learning and memory 
retrieval (Andrews-Zwilling et al., 2010). Increased inhibitory synaptogenesis and inhibitory 
synaptic GABA content (Jasinska et al., 2010), coupled with prolonged synaptic inhibition onto 
excitatory neurons in rodents while learning, stresses the importance of the role of inhibitory 
synaptic plasticity in this process (Brosh and Barkai, 2009). Therefore, targeting the GABA system 
to dampen neuronal excitability in various brain regions and correcting the excitatory/inhibitory 
imbalance may be important in AS. Increasing the signal-to-noise ratio in the AS brain may 
improve the detrimental motor, seizure, and cognitive phenotypes of this disorder. 
 
Ganaxolone 
 
Ganaxolone is a 3β-methylated synthetic analog of allopregnanolone, a metabolite of 
progesterone and positive allosteric modulator of the GABAA receptor (Carter et al., 1997; Nohria 
and Giller, 2007). Allopregnanolone is synthesized in the brain via A-ring reduction of 
progesterone by 5α-reductase and 3 α-hydroxysteroid-oxidoreductase isoenzymes (Kokate et al., 
1999; Reddy, 2009). This inhibitory neurosteroid has natural anticonvulsant properties, and its 
concentration increases within 15 minutes following seizure episodes to control neuronal 
excitability (Galli et al., 2001). However, allopregnanolone is rapidly oxidized into a neuronally 
inactive form at the 3α-hydroxy position, and can also undergo conversion back to hormonally 
active intermediates, making it difficult to administer as an anticonvulsant (Carter et al., 1997). 
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Therefore, ganaxolone was synthesized and modified to mimic allopregnanolone, but with a longer 
half-life and without enzymatic conversion to a hormonally active steroid (Nohria and Giller, 
2007). The route of ganaxolone administration varies in rodents from oral gavage to subcutaneous 
or intraperitoneal injection, as neurosteroids synthesized in the periphery are highly lipophilic and 
can readily cross the blood-brain barrier (Belelli and Lambert, 2005). Therefore, direct brain 
delivery of ganaxolone is unnecessary.  
Ganaxolone is a selective modulator that binds with high affinity to both the synaptic α1/2 
and extrasynaptic δ subunits of the GABAA receptors, affecting both phasic and tonic inhibition, 
respectively (Reddy and Woodward, 2004; Reddy and Rogawski, 2010). Like other neurosteroids, 
this drug binds to unique sites on the GABAA receptor located within the transmembrane domains 
of the α- and β-subunits, altering channel open frequency and duration (Reddy, 2011). The ability 
of ganaxolone to directly activate synaptic GABAA receptor function at high (mM) concentrations 
and potentiate extrasynaptic GABAA receptors at lower concentrations (nM) by increasing both 
channel-open frequency and duration may significantly alter anxiety, stress, neuronal excitability, 
and ultimately seizure susceptibility (Heulens et al., 2012; Greenfield, 2013). Previous reports 
demonstrate the powerful anticonvulsant effects of this drug in various rodent seizure models, 
including cocaine and cornea-kindled, chemically-induced, maximal electroshock, and audiogenic 
seizure-susceptible animals (Carter et al., 1997; Heulens et al., 2012). An additional study also 
demonstrated both behavioral and electrographic seizure suppression in an amygdala-kindled 
mouse model at an ED50 of 6.6 mg/kg (estimated dose resulting in 50% inhibition) (Reddy and 
Rogawski, 2010). Moreover, chronic neurosteroid treatment results in a low propensity to 
tolerance compared to benzodiazepines; therefore, the same effective dosage can be used for long 
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periods of time (Reddy and Rogawski, 2000). This distinguishes ganaxolone from common AEDs, 
where the prescribed dosage gradually increases over time, and outbreak seizures can occur. 
Currently, ganaxolone has been successful in clinical trials of drug-resistant partial-onset 
seizures, pediatric epilepsy, and migraines, and is well-tolerated in both adults and children with 
minimal side effects (Monaghan et al., 1997). The most commonly reported side effect is reversible 
dose-dependent somnolence (Pieribone et al., 2007; Reddy, 2011). It has also been shown to be 
orally active with an excellent safety profile, and plasma levels are maintained in humans with two 
or three times daily dosing (Monaghan et al., 1997; Monaghan et al., 2005). An ongoing clinical 
trial is investigating the use of ganaxolone as an anxiety and attention treatment in children with 
Fragile X syndrome, a genetic syndrome similar to AS, with documented imbalances in excitatory 
glutamatergic and inhibitory GABAergic neurotransmission (Paluszkiewicz et al., 2011). 
Ganaxolone is the only neurosteroid evaluated thus far in human clinical trials for the treatment of 
epilepsy (Reddy and Woodward, 2004; Reddy, 2011).  
 
The Ketogenic Diet and Ketone Bodies 
The ketogenic diet (KD) is a high-fat, low-carbohydrate, low-protein diet that mimics 
metabolic fasting and has been utilized as an epilepsy treatment since the 1920s (Lutas and Yellen, 
2013). The KD involves long-chain saturated triglyceride consumption in a 3:1 or 4:1 KD ratio of 
fats to carbohydrates and protein by weight. Following an initial period of fasting, implementation 
of the KD leads to ketone body production by the liver. Ketone bodies can be metabolized as an 
alternative to glucose for energy or as essential components of phospholipids, which contribute to 
cell membrane construction. While the KD is frequently utilized clinically in cases of refractory 
epilepsy in infants (Kossoff et al., 2002), adolescents (Mady et al., 2003), and adults (Coppola et 
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al., 2002) independent of gender (Bough and Rho, 2007), very little is understood regarding its 
underlying anticonvulsant mechanism(s) of action. 
Chronic ketosis is a key feature of the KD, as ketone bodies (β-hydroxybutyrate (BHB), 
acetoacetate (AcAc), and acetone) are produced as a result of β-oxidation by the liver 
(Schwartzkroin, 1999). Ketone bodies are then transported from the liver to other tissues, where 
BHB and AcAc are reconverted to acetyl-CoA to produce energy via the TCA cycle and oxidative 
phosphorylation. Acetone is produced by spontaneous decarboxylation of AcAc, and if not used 
for energy is removed as waste, as it cannot be converted back to acetyl-CoA (Laffel, 1999). 
 
Potential Anticonvulsant Mechanisms of the Ketogenic Diet 
The KD typically exerts its maximal anti-epileptic effects in both rodents and humans 
several days or weeks following initiation, suggesting the diet may trigger several metabolic and/or 
genetic alterations to modify and possibly enhance cellular metabolism (Bough and Rho, 2007; 
Masino and Rho, 2012). These changes may help counter neuronal damage and dysfunction 
resulting from epilepsy. Potential KD mechanisms include decreased reactive oxygen species 
(ROS) production, enhanced mitochondrial function and mitochondrial biogenesis, reduced 
inflammatory mediators, enhanced activity of neurotrophic factors, and increased 
[GABA]:[glutamate] (Bough and Rho, 2007; Maalouf et al., 2009). Each of these alterations are 
reported following increased ketone body production by the liver, typically as a result of chronic 
ketosis.  
Ketone body production. Both animal and clinical data suggest the underlying anti-
epileptic efficacy of the KD is attributed to a metabolic shift from glycolysis to fatty acid oxidation 
and increased plasma ketone levels, specifically AcAc and acetone (Bough and Rho, 2007). A 
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typical diet will yield <0.5 mM of plasma ketone bodies in normal, healthy human subjects (Jain 
et al., 1998). However, during ketosis, ketones can rise to levels between 0.5 mM and 5 mM, with 
adults averaging between 4 mM and 7 mM following two weeks of fasting. Small rodents can 
achieve 2-3 mM during starvation, although plasma ketone levels typically remain <1 mM (Cahill 
Jr, 2006). Accumulation of plasma ketone bodies while on a ketogenic diet leads to ketone body 
transportation across the blood-brain barrier via facilitated diffusion mediated by monocarboxylate 
transporters (MCT), specifically MCT1 (Klepper, 2008; Prins, 2008). 
In rodent seizure models, both acetone and AcAc have demonstrated the greatest potential 
for protection against recurring seizures (Keith, 1933; Rho et al., 2002; Likhodii et al., 2003; 
Bough and Rho, 2007). For example, intraperitoneal acetone injections into rats exhibited a broad 
spectrum of anticonvulsant effects in models of tonic-clonic seizures (maximal electroshock), 
absence epilepsy (subcutaneous pentylenetetrazol injection), complex seizures with secondary 
generalization (amygdala kindling), and atypical absence seizures (AY-9944 test), and yielded 
plasma and cerebrospinal fluid (CSF) concentrations directly proportional to the injected dose 
(Likhodii et al., 2003). In humans with well controlled epilepsy, acetone levels up to 1 mM were 
detected in the brains of five of seven patients using non-invasive proton magnetic resonance 
spectroscopy, providing further evidence of the contribution of acetone in conferring seizure 
protection (Seymour et al., 1999). Initial evidence of the anticonvulsant activity of AcAc was 
demonstrated by Keith (1933) in thujone-induced seizures in rabbits. Work by Rho et al. (2002) 
supported this claim, reporting both AcAc and acetone seizure protection in a mouse model of 
audiogenic seizures. Recent evidence suggests AcAc inhibits vesicular glutamate transporters by 
competing with Cl- at the site of allosteric regulation, suppressing glutamate release and 4-
aminopyridine-induced seizures in rats (Juge et al., 2010).  
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Although previous studies have consistently reported the anticonvulsant actions of both 
acetone and AcAc in vivo, evidence for BHB has been lacking. However, recent work suggests 
BHB increases pilocarpine-induced seizure thresholds in both young (Yum et al., 2012b) and 
mature (Yum et al., 2012a) mice. Moreover, BHB also attenuates NMDA-induced spasms in a rat 
model of cryptogenic infantile spasms (Yum et al., 2015). Nonetheless, there is no strong evidence 
to indicate primary mechanistic anticonvulsant activity for either AcAc or BHB thus far, 
suggesting adaptations to ketosis only partially contributes to the anti-epileptic properties of the 
KD. Furthermore, the use of exogenous ketones has not been examined as a treatment for epilepsy 
in human patients, and therefore clinical application is unclear. 
Decreased blood glucose. It has been hypothesized that any diet that induces chronic 
ketosis and decreases blood glucose can produce anticonvulsant effects, as caloric restriction alone 
can alter seizure susceptibility (Greene et al., 2001; Greene et al., 2003). Caloric restriction could 
decrease glycolytic energy which is crucial for maintaining high levels of synaptic activity, and 
the reduced energy available from glycolysis may alter the brain’s ability to initiate and propagate 
seizure (Greene et al., 2001). Previous work has demonstrated decreased blood glucose 7 and 14 
days following KD initiation in a mouse model of systemic metastatic cancer (Poff et al., 2013), 
and 4 weeks after KD administration in two Alzheimer’s disease mouse models (Brownlow et al., 
2013).  
The role of decreased glucose in providing anticonvulsant activity in the KD is also 
supported by work involving 2-deoxyglucose (2-DG), a glucose analogue, which inhibits 
glycolysis via phosphoglucose isomerase inhibition. 2-DG decreases epileptiform burst activity 
and is anticonvulsant in several rodent models of epilepsy, including 6-Hz corneal stimulation, 
perforant path kindling, and audiogenic seizures in Fring’s mice (Stafstrom et al., 2009). This 
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compound has also slowed the progression of kindling in a rat model of temporal lobe epilepsy, 
suggesting inhibition of glycolysis may play an important role in the ability of the KD to control 
seizures (Garriga-Canut et al., 2006).  
Enhanced energy metabolism. Several studies have described metabolic alterations 
following the KD that could directly or indirectly enhance energy production. KD administration 
increases metabolic efficiency by upregulating genes associated with oxidative phosphorylation, 
enhancing mitochondrial biogenesis in the hippocampus, and increasing brain ATP concentration 
and other bioenergetic substrates in the rodent brain (Devivo et al., 1978; Nakazawa et al., 1983; 
Bough et al., 2006). The KD also decreases the respiratory quotient and maximal mitochondrial 
respiratory rate in rodents (Bough and Rho, 2007). Impaired metabolic or mitochondrial 
dysfunction has been reported in epileptic patients and in experimental models of epilepsy (Kunz 
et al., 2000; Kudin et al., 2002; Kann et al., 2005), which further supports the idea that alterations 
in oxidative phosphorylation and increased energy production via the KD may ultimately have 
neuroprotective, anticonvulsant properties.  
Increased brain energy substrates and ATP concentrations may also lead to stabilized 
synaptic transmission and increased seizure resistance via enhanced or prolonged activation of 
Na+/K+-ATPase. It has been postulated that sodium-potassium pump alterations may help maintain 
neuronal ionic gradients and stabilize the resting membrane potential, allowing neurons to become 
more resistant to depolarization, although this notion has not been tested directly. Previous work 
has also demonstrated that tissue from rats fed a KD is more resistant to metabolic stress following 
moderate induction of hypoglycemia, as evidenced by enhanced maintenance of synaptic 
transmission in the dentate gyrus compared to control diet slices (Bough et al., 2006). The ability 
of the KD or ketone bodies to enhance energy preserves and decrease ROS production via 
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increased NADH oxidation (Maalouf et al., 2007) may provide CNS protection via preservation 
of neuronal dysfunction and stabilization of synaptic transmission during periods of high metabolic 
stress (i.e., seizure episodes).   
GABAergic alterations. The KD has shown to be most effective in seizure models 
involving GABAergic antagonists (i.e., PTZ, bicuculline, picrotoxin) compared to those involving 
ionotropic glutamate receptors or sodium channels, suggesting GABAergic transmission may be 
a critical component of the diet’s action. Electrophysiological work also supports this idea, as 
slices from rats fed a KD demonstrate reduced network excitability via increased paired-pulse 
inhibition in the dentate gyrus (Bough et al., 2003). This suggests the diet may limit network 
excitability via attenuation of network excitability and enhancement of GABAergic inhibition. 
Moreover, mild ketosis resulting from caloric restriction increases mRNA levels and protein 
expression of both isoforms of glutamic acid decarboxylase (GAD65 and GAD 67), an enzyme 
essential for GABA synthesis, in multiple brain regions (Cheng et al., 2004).  
Additionally, it has been hypothesized that in chronic ketosis, alterations in brain amino 
acid handling occurs, resulting in a shift of the equilibrium of the aspartate aminotransferase 
reaction (Figure 1.1) (Yudkoff et al., 2007). This would lead to a reduction of aspartate relative to 
glutamate, the precursor to GABA synthesis, predicting an increase in GAD activity and GABA 
production.  It has also been shown that BHB may increase the available pool of GABA by 
decreasing GABA degradation via suppression of GABA-transaminase activity (Suzuki et al., 
2009), and clinical work has demonstrated significant increases in CSF and brain GABA levels 
following KD treatment (Wang et al., 2003; Dahlin et al., 2005). An elevation in GABA production 
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or accumulation would likely decrease hyperexcitability and increase GABAergic function, 
resulting in improved seizure control. 
Figure 1.1. Neuronal metabolic modifications of glutamate and GABA synthesis during ketosis. 
Beta-hydroxybutyrate, acetoacetate, and acetone increase upon ketogenic diet consumption. All 
ketone bodies generate acetyl-CoA and are metabolized in the TCA cycle via the citrate synthase 
pathway. This diminishes the availability of oxaloacetate, which is involved in the transamination 
of glutamate to aspartate. Less glutamate is converted to aspartate and more is available for the 
conversion of glutamate to GABA via glutamic acid decarboxylase in GABAergic neurons. 
Astrocytes convert acetate to glutamine which can be exported to GABAergic neurons for the 
ultimate production of GABA.  
 
*This figure has been previously published in Annual Review of Nutrition, 2007, 27: 415-430, and 
has been reproduced with permission from Annual Reviews. See Appendix B. 
 
Ketone Ester Supplementation 
Despite the efficacy of the KD, it can be difficult to produce palatable meals when 
following a strict 4:1 KD ratio, and the diet itself can cause digestive issues, such as constipation. 
Additionally, the KD produces only moderately enhanced ketone levels compared to prolonged 
fasting (Cahill Jr, 2006). Moreover, both clinical and experimental observations suggest that 
sustained ketosis and decreased glucose results in anticonvulsant efficacy regardless of dietary 
composition (Bough and Rho, 2007). Therefore, ketone esters (KEs) of both AcAc and BHB have 
been manufactured to mimic sustained ketosis without dietary restriction (Desrochers et al., 1995). 
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KEs can be utilized as supplementation to any diet (i.e., standard, ketogenic, or low-glycemic index 
treatment (LGIT)) in order to boost ketone levels and potentially improve clinical effectiveness of 
dietary therapies. Moreover, previous work has demonstrated the combination of the KD and KE 
significantly increases blood BHB and decreases blood glucose more than KD administration 
alone in a mouse model of metastatic cancer (Poff et al., 2015).  
KEs may be an ideal treatment option for patients with developmental disorders such as 
AS, in which several case studies have demonstrated significant efficacy of the KD (Valente et al., 
2006; Evangeliou et al., 2010; Stein et al., 2010). Additionally, it has been reported that patients 
treated with the classic KD exhibit at least a 50% reduction in seizure frequency (Bough and Rho, 
2007). Moreover, patients with AS may respond to dietary therapies with a greater efficacy, as 
>90% seizure reduction has been observed in these patients following one year on an LGIT diet 
(Thibert et al., 2012). The KD has also demonstrated success in a variety of seizure models and 
types. AS patients typically present with multiple seizure types that are commonly frequent and 
prolonged, and the KD may have a significant effect on seizures in this disorder (Thibert et al., 
2013). Therefore, a viable epilepsy treatment such as the KD or KE is necessary to address these 
concerns. However, sensory abnormalities can often lead to gagging and food intake issues when 
a meal plan is altered with the KD in AS, and some children have difficulty gaining and/or 
maintaining weight (Laan et al., 1999). 
The R,S-1,3-butanediol-acetoacetate diester (BD-AcAc2) is a source of supplemental 
ketone bodies which significantly elevates blood ketone concentrations regardless of diet. This 
ketone ester is a synthetic precursor of ketone bodies and is comprised of two AcAc molecules 
esterified to one molecule of 1,3-butanediol, an organic alcohol commonly used as an additive for 
flavoring agents. When ingested, digestive esterases cleave the ester into two AcAc molecules, 
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which are then absorbed into the bloodstream and rapidly elevate plasma ketone concentration. 
The 1,3-butanediol is metabolized by the liver to produce β-hydroxybutyraldehyde, which is 
rapidly oxidized to β-hydroxybutyrate, further increasing plasma ketone levels. BD-AcAc2 has 
induced therapeutic ketosis in dogs, pigs, and rodents (Desrochers et al., 1995; Puchowicz et al., 
2000; D'Agostino et al., 2013; Poff et al., 2014; Viggiano et al., 2015). BD-AcAc2 has also 
demonstrated positive results in rat models of seizure, including central nervous system oxygen 
toxicity (CNS-OT) and pentylenetetrazol (PTZ), elevating BHB in the PTZ model and AcAc, 
BHB, and acetone in the CNS-OT model. Both studies reported a significant increase in seizure 
latency, and this work establishes a foundation for BD-AcAc2 use in other seizure models 
(D'Agostino et al., 2013; Viggiano et al., 2015).  
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CHAPTER TWO: 
 
KETONE ESTER SUPPLEMENTATION ATTENUATES SEIZURE ACTIVITY, AND 
IMPROVES BEHAVIOR AND HIPPOCAMPAL SYNAPTIC PLASTICITY IN AN 
ANGELMAN SYNDROME MOUSE MODEL2 
 
Abstract 
Angelman syndrome (AS) is a rare genetic and neurological disorder presenting with 
seizures, developmental delay, ataxia, and lack of speech. Previous studies indicate oxidative 
stress-dependent metabolic dysfunction may underlie phenotypic deficits reported in AS mice. 
While the ketogenic diet (KD) protects against oxidative stress and successfully treats refractory 
epilepsy in AS case studies, issues arise due to its strict adherence requirements, in addition to 
selective eating habits and weight issues reported in AS patients. We hypothesized ketone ester 
(KE) supplementation would mimic the KD as an anticonvulsant and improve behavioral and 
synaptic plasticity deficits in vivo. AS mice were fed a KE diet ad libitum for eight weeks, and 
improvements in motor coordination, learning and memory, and synaptic plasticity were reported. 
The KE was also anticonvulsant and altered brain amino acid metabolism in AS treated animals. 
Our findings suggest KE supplementation produces sustained ketosis and ameliorates many 
phenotypes in the AS mouse model, and should be investigated further for future clinical use. 
                                                 
2 Portions of this chapter have been previously published in Neurobiology of Disease, 2016, 4: 38-46, and have been 
legally reproduced under the Creative Commons Attribution (CC-BY) license and are utilized with the permission of 
the publisher. See Appendix B. 
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Introduction 
Angelman syndrome (AS) is a devastating neurological disorder with a prevalence of 1 in 
15,000 that currently has no treatment (Williams et al., 2010). AS often presents with ataxia, 
frequent smiling and laughter, lack of speech, and severe, debilitating seizures (Valente et al., 
2006; Pelc et al., 2008; Williams et al., 2010). It is estimated that approximately 80% of individuals 
with AS have epilepsy, with difficulty in controlling seizures being a primary reason for patient 
hospitalization (Valente et al., 2006; Pelc et al., 2008; Thibert et al., 2009). Epilepsy in AS is often 
refractory to many prescribed medications, and frequently involves many seizure types (Valente 
et al., 2006; Pelc et al., 2008; Thibert et al., 2009). Approximately 70% of AS cases involve 
deletion within 15q11.2-q13.1 and generally exhibit increased frequency and severity of seizure. 
The larger deletions include the gene encoding the GABAA receptor β3 subunit, leading to cortical 
hyperexcitability and seizure activity. Importantly, chronic, intractable epilepsy has been shown 
to cause hippocampal damage and is associated with cognitive decline (Helmstaedter et al., 2003). 
Effective anti-epileptic drugs (AEDs) are limited in AS, and those medications are generally 
known to have side effects that can alter cognition (Drane and Meador, 1996; Campos-Castello, 
2006; Mula and Trimble, 2009). Therefore, it is crucial to find or develop novel therapeutics to 
treat this aspect of the disorder. 
 Recent findings demonstrate an overall decrease in cortical and cerebellar inhibition in AS 
mice, and dietary therapies may help overcome this imbalance and affect neuronal excitability 
(Egawa et al., 2012; Thibert et al., 2012; Wallace et al., 2012). Both the ketogenic diet (KD), a 
high fat, low carbohydrate, moderate protein diet, and the low-glycemic index treatment (LGIT), 
a high fat diet with limited carbohydrates, are described as well-tolerated and successful in case 
reports involving patients with AS (Valente et al., 2006; Evangeliou et al., 2010; Stein et al., 2010; 
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Thibert et al., 2012). Additionally, the KD has been shown to stimulate mitochondrial biogenesis, 
which can improve some of the hippocampal deficits in AS mice (Bough et al., 2006; Su et al., 
2011), and enhances motor performance in neurological and neurodegenerative disorders 
(Friedman et al., 2006; Mantis et al., 2009; Beckett et al., 2013; Brownlow et al., 2013). However, 
non-pharmacological management is rarely considered and little data has been published on 
dietary therapies in AS (Pelc et al., 2008; Thibert et al., 2009), limiting additional information 
regarding efficacy of the KD in the overall AS population. Additionally, investigation of the KD 
in AS specifically is hampered by individuals having selective eating habits, weight loss, and 
difficulties gaining weight (Clayton‐Smith, 1993; Clarke and Marston, 2000). 
 Oral administration of ketone esters, which mimic the KD and are precursors to ketone 
bodies, may help circumvent Angelman syndrome-specific issues, as they have been shown to 
significantly elevate blood ketones in rats (D'Agostino et al., 2013) independent of carbohydrate 
restriction (Kesl et al., 2016). Preliminary work also suggests ketone esters elevate blood ketones 
and are generally safe and well-tolerated in healthy human patients (Clarke et al., 2012; Kemper 
et al., 2015). A number of hypotheses have sought to isolate the neuroprotective and anticonvulsant 
mechanism(s) underlying ketosis, including a metabolic shift of [GABA/glutamate], resulting in 
increased tonic inhibition (Bough and Rho, 2007; Yudkoff et al., 2007). Therefore, the use of 
therapeutics that increase the GABA/glutamate ratio may serve to dampen overall neuronal 
excitability in various areas of the brain, resulting in decreased seizure activity. 
In this study, we evaluated the potential of a ketone ester (KE), R,S-1,3-butanediol 
acetoacetate diester (BD-AcAc2), to induce therapeutic ketosis in an AS mouse model and act as 
an anticonvulsant. Additionally, we examined the effects of the ketone ester on behavioral and 
metabolic outcomes in our mouse model. We hypothesized that supplementation of BD-AcAc2 
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with a standard diet would mimic results of the KD as an anticonvulsant and a treatment for the 
cognitive and motor dysfunction reported in AS.  
 
Materials and Methods  
Animals 
UBE3Atm1Alb/J null mutation (AS) mice, described previously (Jiang et al., 1998)  were 
purchased from the Jackson Laboratory. Wild-type (WT) and AS mice were obtained through 
breeding of heterozygous female mice with WT males to produce maternally-deficient AS 
offspring and age-matched, wild-type littermate controls. Animals were housed with a standard 12 
hour light/dark cycle and supplied with food and water ad libitum at the University of South 
Florida, and were housed in groups of three to four per cage. Experiments were performed on 12-
14 week-old male and female mice. All animal testing procedures and care followed the NIH 
guidelines and were approved by the University of South Florida’s Institutional Animal Care and 
Use Committee (Approval ID number A4100-01). 
 
Ketone Ester Administration 
4-6 week-old experimental and control mice were fasted for 8 hours prior to initial ketone 
ester administration and study initiation to ensure rapid feeding compliance and to establish a 
similar metabolic starting point as previously described (Poff et al., 2014). Control mice were fed 
standard rodent chow (Teklad 2018) ad libitum. Mice receiving the ketone supplement were 
administered BD-AcAc2 with their standard rodent chow ad libitum. These mice received standard 
rodent chow mixed at 10% BD-AcAc2 by volume and 1% saccharin for palatability (Sigma-
Aldrich) as previously described (Poff et al., 2014), which prevented food aversion observed in 
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initial pilot studies. The KE was synthesized in collaboration with Savind, Seymour IL, as 
previously described (D'Agostino et al., 2013). Diets were continuously monitored and replaced 
twice weekly or as needed to maintain freshness for 8 weeks. 
 
Blood and Weight Measurements 
Blood was collected once weekly from the tail using approved methods. Behavioral testing 
was not performed on these days, and food availability was limited for four hours and returned for 
two hours prior to blood collection. Blood glucose and β-hydroxybutyrate (BHB) were measured 
with the Precision XtraTM Blood Glucose & Ketone Monitoring System (Abbott Laboratories). 
Mice were weighed twice weekly for the duration of the study and were removed from 
experimentation if >20% of their initial body weight was lost. For measurement of plasma ketones, 
blood samples (200μl) were collected into heparinized Eppendorf tubes. Samples were processed 
for the detection and quantification of BHB and acetoacetate (AcAc) at Case Western Reserve 
University, Mouse Metabolic Phenotyping Center. Blood samples were chilled on ice for 30s and 
centrifuged in a microcentrifuge (13,000g) for 3–5 min. Plasma was removed and immediately 
frozen on dry ice before being stored at −80°C. Samples were stored at −80°C until analyzed for 
ketones. Internal standards of [2H6]BHB or [
2H8]isopropanol were added to the treated plasma 
samples (50 μl) and the BHB and AcAc (as M+1 of BHB) were analyzed by gas chromatography-
mass spectrometry (GC-MS) using an Agilent 5973 mass spectrometer, linked to a 6890 gas 
chromatograph equipped with an autosampler. Briefly, GC-MS conditions were either electron 
ionization (EI) mode or chemical ionization (CI) mode; the samples were detected by selected ion 
monitoring as the BHB- and AcAc-trimethylsilyl derivatives (EI). 
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Behavioral Testing 
Open field behavior was assessed to determine general locomotor activity and anxiety. 
Mice were placed in an acrylic chamber (40cm x 40cm x 27cm) and were allowed to explore for 
15 minutes. ANY-Maze animal activity system (Stoelting Co.) was used to monitor movement and 
distance traveled. 
Elevated plus maze was used to assess anxiety levels in the mice. The EPM consisted of 
four arms: two (30 cm x 5 cm) open, well-lit arms and two (30 cm x 5 cm x 15 cm) enclosed arms 
facing each other. Each arm attached to a common open square center platform (4.5 cm). Mice 
were placed in the center platform and allowed to explore for 5 min. A digital camera (XV-BP330, 
Panasonic) was used to monitor activity, and ANY-Maze animal activity system (Stoelting Co.) 
was used to record and analyze behavior. Total time spent in open arms versus closed arms was 
measured, and anxiety levels were assessed by comparing percent time spent in the open arms. 
Rotarod was used to assess motor coordination, motor learning and stamina. Mice were 
placed on a 3 cm diameter rod with an initial rotation of 4 rpm and accelerated to 40 rpm over a 
maximum of 5 min (Ugo Basile, Italy). Mice were tested for latency to fall off the rod for four 
trials per day for two consecutive days. 
Wire hang test was used to measure subacute muscle function and fatigue. A horizontal 
wire (2 mm in diameter, 40 cm in length) was suspended above a padded table. The animal was 
allowed to cling to the middle of the wire with its forepaws for one 60 sec trial, and latency to fall 
was recorded. 
Hind limb clasping is used as a marker for neurological dysfunction, including certain 
ataxias. The clasping test evaluated the animal’s hind limb response during tail suspension 10 cm 
above their home cage. If the hind limbs were consistently splayed outward, away from the 
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abdomen, the mouse was assigned a score of 0. If one hind limb was retracted toward the abdomen, 
the animal received a score of 1. If both hind limbs were partially retracted toward the abdomen, 
it received a score of 2. If the animal’s hind limbs were entirely retracted and touching the 
abdomen, it received a score of 3. 
Fear conditioning was used to assess hippocampal function and memory formation. Mice 
were placed in a 25 cm x 25 cm sound attenuation chamber with a wire grid flooring. Mice were 
allowed to explore the context for 3 min before they received the conditioned stimulus (CS, 90 db 
tone) for 30 sec. At the end of the 30 sec, mice received a mild foot shock (0.5mA, unconditioned 
stimulus, US). After 1.5 min, the mice received a second CS/US pairing and monitoring continued 
for 1.5 min after food shock administration. 24 hrs following CS/US presentation, mice were 
placed back into the chamber and allowed to explore for 3 min. Learning was assessed by 
measuring freezing behavior consisting of lack of motion for at least 2 consecutive sec. 
Novel object recognition was used to evaluate recognition memory. Each mouse was 
habituated in the test arena (40 cm x 40 cm) for 10 min. 24 hrs following habituation, two identical 
objects similar in size to the mouse were placed along the center line of the arena approximately 
3-5 cm from the outside wall, and mice were allowed to explore for 10 min. 24 hrs following 
training, a novel object replaced one of the familiar objects presented during the training session, 
and mice were allowed to explore for 5 min. Animals were monitored and behavior was quantified 
by video tracking (ANY-Maze, Stoelting, IL).  
 
Audiogenic Seizures 
For audiogenic seizure testing, a separate cohort of mice were habituated to a sound 
attenuation chamber for 60 sec and exposed to sound stimulation (115 dB) for 60 sec or until tonic 
 40 
 
or clonic episodes occurred. An occurrence of sound-induced seizure was defined as tonic, clonic, 
or tonic-clonic seizures during sound stimulation. Animals were tested only once. Seizure testing 
was carried out between 1:00 PM and 6:00 PM to limit effects of diurnal variation on results. 
 
Kainic Acid Injections 
Seizures were induced in a separate cohort of mice by intraperitoneal injection of kainic 
acid (KA) at 20mg/kg. Following injection, animals were returned to cages where seizure severity 
was assessed at 5-min intervals for up to 50 min according to a modified Racine’s scale (Dunleavy 
et al., 2013). 
 
Extracellular Recordings 
Following behavioral testing, a cohort of mice was euthanized and the hippocampi 
dissected out to be used in hippocampal LTP experimentation as previously described (Trotter et 
al., 2013). The brain was rapidly dissected and placed in ice-cold, oxygenated cutting solution 
containing (in mM): 110 sucrose, 60 NaCl, 3 KCl, 28 NaHCO3, 1.25 NaH2PO4, 5 glucose, 0.6 
ascorbate, 7 MgCl2, and 0.5 CaCl2. Hippocampal slices (400 μm) were prepared on a vibratome 
and allowed to equilibrate in a 50% cutting saline and 50% artificial cerebrospinal fluid solution 
containing (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose, 1 MgCl2, and 2 
CaCl2. Slices were maintained in this solution with constant 95% O2/5% CO2 perfusion for 10 min 
before being transferred to the brain slice recording chamber supported by nylon mesh or 
maintained in a holding container. Slices were recovered for a minimum of 1 h before recording. 
The recording chamber was held at 30° ± 0.5°C with a ACSF flow rate of 1 ml/min. Field EPSPs 
(fEPSPs) were recorded from stratum radiatum in hippocampal area CA1 via glass microelectrodes 
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filled with artificial cerebrospinal fluid (resistance 1–4 mΩ). Responses were generated by 
stimulation of Schaffer collaterals arising from the CA3 region. Stimulating electrodes consisted 
of formvar-coated nichrome wire, which was used to deliver biphasic stimulus pulses (1–15 V, 
100 μs duration, 0.05 Hz). Delivery of stimulation, controlled by pClamp 9.0 software (Molecular 
Devices), was via the Digidata 1322A interface (Molecular Devices) and a stimulus isolator 
(model 2200; A-M Systems). Signals were amplified using a differential amplifier (model 1800; 
A-M Systems), filtered at 1 kHz, and digitized at 10 kHz. For all experiments, baseline stimulus 
intensity was set at the level that elicited ∼50% of the maximum fEPSP response as determined 
from the input–output curve. The input–output relationship was determined by stimulating slices 
from 0 to 15 mV at 0.5 mV increments. Short-term plasticity was measured via paired-pulse 
facilitation (PPF), which was induced by stimulating slices at half-max intensity with sequential 
pulses spaced at 20 ms intervals from 20 to 300 ms. LTP was induced by a theta-burst protocol, 
which consisted of five trains of four pulse bursts at 200 Hz separated by 200 ms, repeated six 
times with an intertrain interval of 10 s. For analysis, the last 10 minutes of recording was averaged 
and compared. 
 
Western Blot Analysis 
Whole hippocampal brain tissue was lysed on ice in lysis buffer (radio-
immunoprecipitation assay buffer supplemented with protease/phosphatase inhibitor cocktail, 
Thermo Scientific) from male mice. Protein concentrations were determined using the BCA 
Protein Assay Kit (Thermo Scientific). Equal amounts of protein from each sample were loaded 
for SDS-PAGE, and transferred to a PVDF transfer membrane. The membranes were blocked in 
0.1 M tris-buffered saline with 0.1% Tween 20 and 5% nonfat milk, then incubated overnight at 
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4°C with primary antibodies anti-E6AP (#A300-352A, Bethyl Laboratories, Inc.), anti-GAD65/67 
(#AB1511, Millipore), and anti-β-actin (#4967L, Cell Signaling Technology) diluted in blocking 
solution. Membranes were washed and incubated with anti-rabbit IgG-HRP secondary antibody 
(Southern Biotech) diluted at 1:2000 in blocking solution. Proteins were detected using Pierce 
ECL Western Blotting Substrate (Thermo Scientific) and audioradiography. The films were 
digitized and optical densities were measured using a high-powered scanner and the software 
program ImageJ (v1.46r, National Institutes of Health). 
  
Metabolic Analysis of Brain Amino Acids 
GABA and glutamate (Glu) were measured in brain homogenate at Case Western Reserve 
University, Mouse Metabolic Phenotyping Center. This approach enabled metabolites to be 
measured with a high degree of sensitivity (Yang et al., 2008; Kombu et al., 2011; Zhang et al., 
2015). 
Analytical methods. Brains were dissected immediately, frozen in liquid nitrogen within 
30 seconds of removal and stored at -80 °C. Hippocampal sections (25-30 mg tissue) were then 
dissected under frozen conditions in dry ice (-80°C). For the isolation of metabolic intermediates 
the frozen tissue samples were then homogenized using an organic solvent mixture containing 5% 
acetic acid and methanol (1:1; methanol to water) (Zhang et al., 2015). Briefly, frozen samples 
were spiked with internal standards (0.1μmol each): [2H6]GABA and [13C5]glutamate, and then 
homogenized with 3 ml of cold methanol-H20 solvent mixture (1:1, v/v) using a Polytron 
homogenizer. 
GC-MS assay. Following homogenization, the homogenates were extracted using a 
mixture of acetonitrile and 2-propanol (3:1), vortexed and centrifuged for 30 minutes at 2500 RCF 
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at 4°C. Extracts were then dried by nitrogen gas for 0.5 hrs or until completely dry and then 
chemically derivatized using MTBSTFA + 1% TBDMCS reagent (N-methyl-N-(tert-
butyldimethylsilyl) trifluoroacetamide + 1% tert-butyldimethylchlorosilane, Regis Technologies, 
Inc. Morton Grove, IL, USA) and reacted at 70°C for 30 minutes. The derivatized products were 
measured under Agilent 6890 Gas-Chromatography and Agilent 5973 Mass Spectrometry (GC-
MS). A DB-17 MS capillary column (30m × 0.25mm × 0.25 µm) was used in all analysis. The 
starting oven temperature was set to 80°C, the pressure was 14.82 psi, and the flow velocity was 
45cm/sec. Temperature was then increased linearly to 220 °C and held for 1 min. The mass 
spectrometer was in electron-impact (EI), sim mode. Ions for glutamate (m/z =432) and GABA 
(m/z =274) were monitored and data acquisition collected and stored for further analysis.  
 
Statistical Analysis 
All data is represented as the mean ± SEM. To compute p values, data was analyzed 
using Student’s t-test and two-way ANOVA with genotype and treatment as main factors 
followed by Bonferroni post hoc tests, set at a significance of p < 0.05 (GraphPad Prism 
software). Statistical outliers that fell outside two standard deviations of the mean were excluded 
from analysis.  
 
Results 
Ketone Supplementation Lowered Blood Glucose, Elevated Blood Ketones, and 
Normalized Body Weight in AS Mice 
Whole blood ketone (BHB) and glucose measurements were similar at baseline between 
all groups, and chronic ketone supplementation resulted in elevated ketones and lowered blood 
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glucose in WT KE and AS KE treated mice (Figures 2.1A and 2.1B, repeated measures ANOVA, 
p < 0.01 and p < 0.0001; WT vs. WT KE, WT vs. AS KE, and AS vs. AS KE p <0.05 and p < 
0.001, respectively). 
Figure 2.1. R,S-1,3-butanediol acetoacetate diester (BD-AcAc2) induces ketosis, lowers glucose, 
and normalizes body weight in WT and AS mice. (A) BD-AcAc2 elevated whole blood β-
hydroxybutyrate (BHB) in treated WT and AS animals compared to controls (WT and AS controls: 
n=15; WT KE: n=16; AS KE: n=20). (B) WT and AS treated mice demonstrated decreased whole 
blood glucose compared to controls following 8 weeks of ketone ester supplementation (WT and 
AS controls: n=15; WT KE: n=16; AS KE: n=20). (C) Both plasma BHB and acetoacetate (AcAc) 
levels were significantly elevated in treated compared to non-treated WT and AS animals 
(n=4/group). (D) AS mice demonstrated a significant increase in body weight while AS KE 
animals had a significant normalization in body weight that was sustained throughout the duration 
of the study (WT and AS controls: n=15; WT KE: n=16; AS KE: n=20; *p < 0.05, **p < 0.01 and 
***p < 0.001). 
 
BD-AcAc2 also significantly increased plasma BHB (Figure 2.1C, ANOVA p < 0.05, F 
(3,13) = 9.156; WT vs. WT KE and AS vs. AS KE p < 0.05) and AcAc (Figure 2.1C, ANOVA p 
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<0.01, F (3,13) = 9.038; WT vs. WT KE and AS vs. AS KE p < 0.05) in WT KE and AS KE compared 
to control animals. Standard high-carbohydrate rodent chow with ketone supplementation also 
significantly decreased body weight in AS mice during the two-month KE treatment, which did 
not differ significantly from WT control body weights by the end of the study (Figure 2.1D, 
repeated measures ANOVA, p < 0.0001; WT vs. AS and AS vs. AS KE p < 0.001, WT vs. AS KE 
p < 0.01). 
 
Ketone Supplementation Had No Effect on General Locomotor Activity or Anxiety 
General locomotion and anxiety were examined in BD-AcAc2 fed mice, in addition to WT 
and standard diet (SD) control animals. There were no significant alterations in general locomotor 
activity and anxiety behavior in animals fed the ketone ester diet, as measured by the open field 
test (Figure 2.2A and 2.2B) and elevated plus maze (Figure 2.2C). 
 
Administration of a Ketone Ester Improved Motor Coordination, Learning, and 
Overall Neurologic Function 
AS mice display abnormalities in gait, motor learning, and motor coordination, as 
evidenced by increased hind stride length and base width and deficits in rotarod, wire hang, and 
paw abduction tests (Jiang et al., 1998; Van Woerden et al., 2007; Heck et al., 2008; Egawa et al., 
2012; Meng et al., 2013). Following two months of BD-AcAc2 administration, AS KE mice 
demonstrated significant improvements in rotarod performance compared to AS controls (Figure 
2.2D, repeated measures ANOVA p < 0.0001; AS vs. AS KE p < 0.01; WT vs. AS and AS KE p 
< 0.001). AS mice displayed significant deficits in the wire hang task, while AS KE diet-fed mice 
showed improvement in wire hang endurance, although not to WT levels (Figure 2.2E). A two-
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way ANOVA revealed a significant effect of genotype (F (1,65) = 43.43, p < 0.0001; interaction of 
group and treatment: p = 0.0667; Bonferroni post-hoc tests: WT vs. AS p < 0.001; AS vs. AS KE 
p < 0.05; WT and WT KE vs. AS KE = p < 0.01). All WT and WT KE mice were able to hang for 
the maximum time of 60 seconds, while 17.6% of AS and 38.8 % of AS KE mice reached the 
maximum trial duration. 
Figure 2.2. Ketone supplementation improves motor coordination but does not affect general 
locomotor activity or anxiety levels in AS mice. (A) Open field: distance traveled. Following 8 
weeks of ketone ester supplementation, mice underwent open-field testing as a locomotor and 
general anxiety control for behavioral testing. Data represent the overall distance traveled in the 
open field. There were no significant differences between experimental groups. (B) Open field: 
time spent in center vs. perimeter. Data represents the ratio of time spent (sec) in the open field vs. 
the perimeter of the field, with no significant differences between groups. (C) Elevated plus maze: 
anxiety levels in WT and AS mice are unaffected with ketone ester supplementation.  Data 
represent percentage of total time spent in open arms of the elevated maze. There were no 
significant differences between experimental groups. (D) Average latency to fall on the 
accelerating rotarod was significantly reduced in AS control animals, while ketone ester 
supplementation significantly enhanced motor performance in AS treated mice. (E) AS mice 
performed poorly on the wire hang task compared to WT controls, while AS KE animals 
demonstrate a significant increase in the latency to fall (WT and AS controls: n=18; WT KE: n=19; 
AS KE: n=20). (F) Severity of the hind limb clasping score was significantly decreased in AS KE-
treated mice (WT and AS controls: n=14; WT KE and AS KE: n=15; *p < 0.05, **p<0.01, ***p 
< 0.001). 
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As previously reported, AS animals also demonstrated a significant hind limb clasping 
phenotype compared to WT controls (Egawa et al., 2012), while AS KE-fed mice showed 
significant improvement (Figure 2.2F). A two-way ANOVA revealed a significant effect of 
genotype (F (1,51) = 90.13, p < 0.0001) and treatment (F (1,51) = 4.16, p < 0.05) with a significant 
interaction of group and treatment (p < 0.05) (Bonferroni post-hoc tests: WT vs. AS p < 0.001; AS 
vs. AS KE p<0.01; WT and WT KE vs. AS KE p < 0.001). 
 
Ketone Supplementation Improves Associative Learning and Recognition Memory in 
AS Mice 
During training, all animals showed similar levels of freezing after presentation of the US 
(Figure 2.3A). Changes in fear memory to the cue were not altered in WT KE, AS KE, or control 
animals (data not shown). AS KE mice had a significant enhancement of associative memory 
similar to WT controls as demonstrated by increased freezing behavior. A two-way ANOVA 
revealed a significant interaction of group and treatment (Figure 2.3B, F (1,55) = 6.98, p < 0.05; 
Bonferroni post-hoc tests: WT vs. AS p < 0.05, AS vs. AS KE p < 0.05). 
AS mice demonstrated impaired exploratory preference for the novel object and KE 
treatment in AS mice reversed the exploratory preference for the novel object to virtually the same 
level as WT mice (Figure 2.3C). A two-way ANOVA revealed a significant effect of treatment (F 
(1,34) = 9.67, p < 0.01) and significant interaction of genotype and treatment (F (1,34) = 8.11, p < 
0.01). (Bonferroni post-hoc tests: WT vs. AS p < 0.05, AS vs. AS KE p < 0.01). The ability to 
discriminate between the familiar and novel object was calculated as the discrimination ratio [(time 
spent exploring novel object – time spent exploring familiar object)/(total time spent exploring 
both objects)] (Figure 2.3D). A two-way ANOVA revealed a significant effect of treatment (F (1,35) 
 48 
 
= 5.90, p < 0.05) and significant interaction of genotype and treatment (F (1,35) = 4.70, p < 0.05). 
Post hoc tests revealed that while there was no significant difference between WT and AS controls, 
KE treatment significantly increased the discrimination ratio in AS mice (ANOVA, p < 0.05 F 
(3,38) = 2.697; AS vs. AS KE p < 0.05). 
Figure 2.3. BD-AcAc2 recovers associative learning and recognition memory deficits observed in 
AS mice. AS mice were trained with a standard 2-shock contextual fear conditioning protocol 
following 8 weeks of treatment. (A) There were no significant differences in freezing between 
experimental groups during training. (B) Contextual fear conditioning was assessed 24 h post-
training. BD-AcAc2 administration increased the average context-dependent freezing in AS KE 
animals compared to nontreated AS mice (WT controls: n=16; AS controls and AS KE: n=18; WT 
KE: n=10; *p < 0.05). (C) Effect of BD-AcAc2 on recognition memory in AS mice in the novel 
object recognition test. Exploratory preference 24 h following training; the dotted line at 50% 
indicates equal preference for both familiar and novel object, indicative of visual memory 
impairment. (D) Effect of BD-AcAc2 on the discrimination index post-treatment. AS KE-treated 
mice demonstrated a significant increase in the discrimination index compared to AS controls (WT 
controls: n=17; WT KE: n=11; AS controls: n=5; AS KE: n=9; *p < 0.05, **p<0.01). 
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BD-AcAc2 Decreases Audiogenic and Chemically-Induced Seizure Activity in AS  
Mice 
Following audiogenic stimulation, we observed seizures in 84% of the AS mice, whereas 
no seizures were observed in WT animals (data not shown). AS KE animals demonstrated a 48% 
reduction in seizure activity as compared to AS controls (Figure 2.4A, p < 0.05 Fisher’s exact test), 
as well as a significant increase in latency to seize (Figure 2.4B, p < 0.05). 
Figure 2.4. Ketone ester supplementation attenuated audiogenic and kainic acid-induced seizure 
activity. (A) Percentage of AS KE and control animals that demonstrated behavioral seizure 
activity following a 115 dB sound stimulation. (B) Latency to seizure following audiogenic 
stimulation was significantly increased in AS KE mice (AS controls: n=11; AS KE: n=13; *p < 
0.05). (C) Kainic acid behavioral seizure scores in AS treated and nontreated animals. Scores were 
tabulated every 5 minutes (AS controls: n=8; AS KE: n=9; *p < 0.01). (D) Latency to behavioral 
seizure score of 2 was significantly increased in AS KE mice (AS controls: n=8; AS KE: n=9; *p 
< 0.05). 
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A significant decrease in behavioral seizure score was recorded 10 and 45 minutes post-
KA injection in AS KE vs AS control animals (Figure 2.4C, Two-way repeated measures ANOVA, 
Bonferroni post-hoc tests, p < 0.01). There was also a significant increase in the latency to a seizure 
score of 2 post-injection (Figure 2.4D, p < 0.05), suggesting an initial delay in seizure severity. 
 
Ketone Ester Supplementation in AS Mice Results in Improvements in Early Phase  
LTP 
Figure 2.5. AS animals given oral ketone ester supplementation show increased LTP induction 
without changes in synaptic transmission. (A) Normal input-output curve at hippocampal SC-CA1 
synapses in WT, WT KE, AS, and AS KE-treated mice. (B) Short-term synaptic plasticity was 
evaluated by the amount of PPF with inter-pulse intervals ranging from 20 to 300 ms. There were 
no significant differences between experimental groups. (C) Long-term potentiation induced by 5 
trains of theta-burst stimulation (arrow). Representative traces are shown for all groups at baseline 
(black trace) and 50 minutes after tetanic stimulation (grey trace). Scale bar = 1 mV and 5 ms. (D) 
LTP induction calculated between 50 and 60 min after TB-stimulation. Data expressed as mean ± 
SEM. (WT = 15 slices, n = 4 mice; WT KE = 14 slices, n = 4 mice; AS = 20 slices, n = 5 mice; 
AS KE = 19 slices, n = 5 mice; p < 0.001). 
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Using a TB-stimulation LTP protocol, the extent of LTP, calculated by averaging the slope 
values of fEPSPs recorded between 50 and 60 minutes after TB-stimulation, was significantly 
lower in slices from AS mice (113.2 ± 0.7) than those from WT animals (165.7 ± 0.73) (Figures 
2.5C and 2.5D, ANOVA, Bonferroni post-hoc tests, p < 0.001). Ketone ester supplementation 
partially rescued impairment of LTP in area CA1 of AS KE mice (Figures 2.5C and 2.5D, 128.5 
± 0.88, p < 0.001) compared to AS mice on the standard diet, although not to the extent of WT 
animals. There were no recorded changes in basal synaptic transmission (input-output relationship, 
Figure 2.5A) or short-term synaptic plasticity (paired-pulse facilitation, Figure 2.5B).  
 
Alterations in Hippocampal GAD65 and GAD67 Expression and GABA/Glutamate  
Ratio Following Ketone Ester Administration 
Figure 2.6. Increased GAD65/67 and GABA/glutamate ratio in the AS mouse hippocampus 
following ketone ester administration. (A) Expression of GAD65 and GAD67 in the hippocampus 
were evaluated in WT, WT KE, AS, and AS KE mice by Western blotting (representative blot 
shown). (B) Densitometric quantification of Western blots in (A) was performed as described in 
Experimental Procedures (n=9 WT and AS KE, n=8 AS, n=4 WT KE). Expression of GAD65 and 
GAD67 was significantly reduced in AS mice compared to WT controls and AS KE animals. (C) 
Brain amino acids GABA and glutamate were measured. The GABA/glutamate ratio is 
significantly decreased in AS mice compared to WT controls and AS treated mice (*p < 0.05, **p 
< 0.01, ***p < 0.001).  
 
Hippocampal protein expression of GAD65/67 was significantly decreased in AS mice 
compared to WT controls by 32.8% and 49.1%, respectively (Figure 2.6A and 2.6B). There were 
no significant changes in GAD65/67 in WT KE mice compared to WT controls. AS KE-fed mice 
displayed significant increases in both hippocampal GAD65 (two-way ANOVA, p < 0.01 F (1,26) 
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= 11.89; WT vs. AS p < 0.01, AS vs. AS KE p < 0.001) and GAD67 (two-way ANOVA, p < 0.01 
F (1,26) = 10.59; WT vs. AS p < 0.05, AS vs. AS KE p < 0.01), comparable to WT levels. Feeding 
a ketone ester diet to AS mice also resulted in a significant increase in the GABA/glutamate ratio 
when compared to standard diet-fed AS animals, similar to WT levels (Figure 2.6C, two-way 
ANOVA, p < 0.05 F (1,13) = 11.55; WT vs. AS p < 0.05, AS vs. AS KE p < 0.01).  
 
Discussion 
Approximately 80% of children with AS have epilepsy, with ~77% of those individuals 
remaining refractory to AEDs (Thibert et al., 2009). These patients are at a high risk of early death 
due to seizures, and many suffer considerable side effects from AEDs. Accordingly, examination 
of alternative therapies should be prioritized. In the present study, we examined the use of a KE to 
induce therapeutic ketosis and improve behavioral phenotypes in the AS mouse model. The major 
findings of this study demonstrate ketosis induced by dietary KE administration, rather than strict 
adherence to a ketogenic diet, is anticonvulsant and improves motor function. Surprisingly, we 
find the KE also improves recognition memory, associative learning, and enhances hippocampal 
synaptic plasticity in AS mice.  
Chronic ketone supplementation decreased blood glucose and body weight and sustained 
ketosis in our AS treated mice, as evidenced by significantly increased plasma and whole blood 
ketones. In addition, eight weeks of KE administration was sufficient to normalize body weight in 
AS mice via chronic ketosis. The ability of the KE to decrease blood glucose has been reported 
previously (Kashiwaya et al., 2010; Poff et al., 2014). It has also been established that ketogenic 
diets can cause weight loss in overweight humans (Astrup et al., 2000; Volek et al., 2004), and 
these adult AS mice are significantly overweight compared to WT controls. KEs can have an 
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appetite suppressing effect via an increase in the anorexigenic metabolite malonyl-CoA, which 
may decrease food intake and, in turn, decrease blood glucose and body weight (Kashiwaya et al., 
2010). It is also important to note that the mice in this study were fed ad libitum, therefore glucose 
and ketone measurements could be affected by variable feeding behavior prior to weekly glucose 
monitoring. Any of these factors could have an effect on the decreased blood glucose and body 
weight seen in the AS KE treated animals. 
In our study, KE-fed AS mice presented an overall improved behavioral phenotype that 
correlates to an equally significant improvement in hippocampal synaptic function. In support of 
our findings, several studies have reported similar effects of ketosis on motor and cognitive 
performance in various rodent models including models of aging, Alzheimer’s disease (AD), 
traumatic brain injury, and amyotrophic lateral sclerosis (Appelberg et al., 2009; Xu et al., 2010; 
Beckett et al., 2013; Brownlow et al., 2013; Kashiwaya et al., 2013; Ari et al., 2014). Furthermore, 
mitochondrial dysfunction has also been reported in the AS mouse model, demonstrated by 
impaired mitochondrial structure and a partial oxidative phosphorylation defect, resulting in 
increased oxidative stress (Su et al., 2011; Llewellyn et al., 2015). Several reports of oxidative 
stress have also been linked to memory deficits in rodents (Fukui et al., 2001; Silva et al., 2004), 
and ketones can induce synaptic protection and prevent oxidative impairment of hippocampal LTP 
(Maalouf and Rho, 2008; Abdelwahab et al., 2015). The data suggest that incorporating ketones 
as alternative fuel substrates into the diet may bypass potential mitochondrial deficiencies and 
protect against oxidative stress, ameliorating some of the behavioral and altered synaptic 
phenotypes in the AS mouse model.  
KE supplementation produced anticonvulsant effects in AS mice in both audiogenic- and 
chemically-induced paradigms, affecting inhibition. However, future studies should extend seizure 
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monitoring following kainic acid injections in order to record potential differences in later seizure 
stages. Both synaptic GAD65 and cytosolic GAD67 are responsible for GABA synthesis, and AS 
mice hippocampi displayed significant decreases in GAD65/67 compared to WT, suggesting 
altered brain amino acid metabolism. AS KE mice demonstrated increased protein expression of 
both enzymes in the hippocampus, indicating a significant alteration in GAD activity. In order to 
explore the potential metabolic alterations further, we measured GABA and glutamate 
concentrations in the hippocampi of AS KE and control mice, and examined the GABA/Glu ratio 
as an indicator of neurotransmitter turnover. The GABA/Glu ratio was significantly increased in 
AS KE mice, suggesting the KE has a significant impact on brain amino acid metabolism, and is 
likely affecting neuronal inhibition. 
Alterations in GAD, GABA, and neuronal inhibition do not solely have an effect on seizure 
activity. Excitatory and inhibitory imbalances have been reported in the AS mouse brain, which 
could affect synaptic function, sensory detection and integration, and result in impaired learning 
and memory (Wallace et al., 2012), although recent findings suggest GABAergic Ube3a loss 
specifically underlies the circuit hyperexcitability in AS (Judson et al., 2016). Decreased 
hippocampal GABA resulting from increases in GAT1, a GABA transporter, impairs learning and 
memory in mice (Hu et al., 2004), and increased GAT1 has been measured in the AS mouse 
cerebellum (Egawa et al., 2012). Learning triggers a rapid increase in GABA content (Jasinska et 
al., 2010), leading to increased GABA released from hippocampal GABAergic interneurons (Nitz 
and McNaughton, 2004; Cui et al., 2008). Increased inhibitory synaptic plasticity and GABA 
release may therefore be essential for learning and memory tasks (Andrews-Zwilling et al., 2012). 
It has been suggested that treatments that alter GABA, GABAergic interneuron function, or 
GABA/glutamate ratio may be beneficial for improving cognition and synaptic plasticity in 
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disorders such as AD (Andrews-Zwilling et al., 2010; Andrews-Zwilling et al., 2012) and AS 
(Egawa et al., 2012; Ciarlone and Weeber, 2016).  
The present findings strongly suggest that KE supplementation in addition to a standard 
diet induces therapeutic ketosis in AS and may be a promising mitigation strategy for many of the 
devastating phenotypes of the disorder, including seizures, motor difficulties, and severe 
developmental delay. With limited treatment options available for human AS, it is important to 
examine this therapeutic option for seizure control and for increased cognitive acuity. Future 
studies will seek to determine its safety and efficacy for potential future clinical trials.   
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CHAPTER THREE: 
 
EFFECTS OF THE SYNTHETIC NEUROSTEROID GANAXOLONE ON SEIZURE 
ACTIVITY AND BEHAVIORAL DEFICITS IN AN ANGELMAN SYNDROME MOUSE 
MODEL 
 
 
Abstract 
 
Angelman syndrome (AS) is a rare neurogenetic disorder characterized by severe 
developmental delay, motor impairments, and epilepsy. GABAergic dysfunction is believed to 
contribute to many of the phenotypic deficits seen in AS. We hypothesized that restoration of 
inhibitory tone mediated by extrasynaptic GABAA receptors could provide therapeutic benefit. 
Here, we report that ganaxolone, a synthetic neurosteroid that acts as a positive allosteric 
modulator of synaptic and extrasynaptic GABAA receptors, was anxiolytic, anticonvulsant, and 
improved motor deficits in the Ube3a-deficient mouse model of AS when administered by 
implanted mini-pump for 3 days or 4 weeks. Treatment for 4 weeks also led to recovery of spatial 
working memory and hippocampal synaptic plasticity deficits. This study demonstrates that 
ganaxolone ameliorates many of the behavioral abnormalities in the adult AS mouse, possibly 
through actions that include positive modulatory effects on extrasynaptic GABAA receptors. 
Tolerance did not occur to the therapeutic effects of ganaxolone. The results support clinical 
studies to investigate ganaxolone as a symptomatic treatment for AS. 
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Introduction 
Angelman syndrome (AS) is a rare neurogenetic disorder characterized by developmental 
delay, speech and motor impairments, easily provoked laughter, and epilepsy (Clayton-Smith and 
Laan, 2003; Williams et al., 2010). AS is associated with maternal deletions of human 
chromosome 15q11-13, resulting in loss of function of the E3 ubiquitin ligase Ube3a (Kishino et 
al., 1997; Matsuura et al., 1997). Deletion of this chromosomal region also often involves 
disruption of the GABAA receptor subunit gene GABRB3, and epilepsy is more prevalent in 
patients with this deletion (Minassian et al., 1998; Røstergaard and Balslev, 2001). Altered 
GABAA receptor function may underlie the epileptic, behavioral, and cognitive abnormalities in 
AS, whether or not GABRB3 is affected (Ciarlone and Weeber, 2015). Decreased tonic inhibition 
has been reported in the Ube3a-deficient AS mouse model, and administration of a selective 
extrasynaptic GABAA receptor agonist improves the abnormal firing properties of Purkinje 
neurons in cerebellar brain slices from these animals and ameliorates motor abnormalities when 
administered in vivo (Egawa et al., 2012). Additionally, Ube3a loss in GABAergic neurons in mice 
leads to cortical hyperexcitability and enhanced seizure susceptibility (Judson et al., 2016). 
Moreover, ratios of GABAA receptor α5/α1 subunit expression in the AS human cortex are 
decreased compared to age-matched controls, consistent with a relative reduction in extrasynaptic 
GABAA receptors inasmuch as α5 subunits are mainly found in extrasynaptically (Caraiscos et al., 
2004) whereas α1 subunits are synaptic (Roden et al., 2010). These various lines of converging 
evidence suggest that deficient tonic inhibition mediated by extrasynaptic GABAA receptors is a 
critical determinant of diverse clinical manifestations in AS. 
 Certain endogenous neurosteroids, such as the progesterone metabolite allopregnanolone, 
are potent positive modulators of synaptic and extrasynaptic GABAA receptors (Reddy, 2010). 
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These neurosteroids exhibit anxiolytic and anticonvulsant actions typical of other GABAA 
receptor positive modulators and they can also enhance cognition as demonstrated by improved 
rodent performance on learning and memory tasks such as the foot-shock active avoidance, passive 
avoidance, and visual discrimination tests (Engel and Grant, 2001; Flood et al., 1992; Isaacson et 
al., 1995; Meziane et al., 1996). Neurosteroids may also facilitate cellular phenomena believed to 
be related to learning and memory such as hippocampal prime-burst potentiation (Diamond et al., 
1996) and long-term potentiation (Yoo et al., 1996). Ganaxolone, the 3β-methyl synthetic analog 
of allopregnanolone, is also a positive allosteric modulator of synaptic and extrasynaptic GABAA 
receptors (Carter et al., 1997; Nohria and Giller, 2007). Unlike allopregnanolone which is devoid 
of oral bioavailability, ganaxolone can be administered orally to obtain meaningful systemic 
exposures (Monaghan et al., 1997; Nohria and Giller, 2007; Reddy, 2010; Reddy and Kulkarni, 
2000). Ganaxolone exhibits protective activity in various seizure models in mice and rats including 
chemiconvulsant, 6 Hz electroshock, and kindling models (Carter et al., 1997; Gasior et al., 2000; 
Reddy and Rogawski, 2010a). Importantly, there is no tolerance to the seizure protection conferred 
by neurosteroids including ganaxolone allowing them to be used chronically in the treatment of 
epilepsy (Reddy and Rogawski, 2000). In limited human clinical trials in adult and pediatric 
patients, ganaxolone has shown indications of efficacy and was well tolerated (Bialer et al., 2013; 
Monaghan et al., 1997; Nohria and Giller, 2007; Reddy and Rogawski, 2010b). 
 In this study, we sought to evaluate the effects of 3 day and 4 week continuous ganaxolone 
treatment on behavior, neurological function and seizure susceptibility of AS mice. We found that 
AS mice demonstrate significant improvements is these diverse domains, whether studied at the 
early or late time point. The results support clinical studies of chronic ganaxolone in the treatment 
of AS. 
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Materials and Methods 
 Animals 
 UBE3Atm1Alb/J null mutation AS mice, described previously (Jiang et al., 1998), were 
purchased from the Jackson Laboratory. Wild-type (WT) and AS mice were obtained through 
breeding of heterozygous female mice with WT males to produce maternal-deficient AS offspring 
and age-matched, wild-type littermate controls. Animals were housed with a standard 12-hour 
light/dark cycle and supplied with food and water ad libitum at the University of South Florida, 
and were housed in groups of three to four per cage. Experiments were performed on 12-14 week-
old male and female mice. All animal testing procedures and care followed the NIH guidelines 
and were approved by the University of South Florida’s Institutional Animal Care and Use 
Committee (Approval ID number A4100-01). 
 
Ganaxolone Administration 
Ganaxolone (ScinoPharm, Taiwan Limited, Tainan, Taiwan) was administered via a 
subcutaneous mid-scapular osmotic pump (Alzet) at 5mg/mL dissolved in aqueous 30% 2-
hydroxypropyl-β-cyclodextrin (BCD) (Sigma-Aldrich) resulting in ~150 nM serum concentration. 
Short- and long-term experiments were completed at 3 days and 4 weeks post-implantation. 
 
Behavioral Testing 
Open field behavior was assessed to determine general locomotor activity and anxiety. 
Mice were placed in an acrylic chamber (40cm x 40cm x 27cm) and were allowed to explore for 
15 minutes. ANY-Maze animal activity system (Stoelting Co.) was used to monitor movement and 
distance traveled. 
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Elevated plus maze (EPM) was used to assess anxiety levels. The EPM consisted of four 
arms: two (30 cm x 5 cm) open, well-lit arms and two (30 cm x 5 cm x 15 cm) enclosed arms 
facing each other. Each arm attached to a common open square center platform (4.5 cm). Mice 
were placed in the center platform and allowed to explore for 5 min. A digital camera (XV-BP330, 
Panasonic) was used to monitor activity, and ANY-Maze animal activity system (Stoelting Co.) 
was used to record and analyze behavior. Total time spent in open arms was measured, and anxiety 
levels were determined by comparing percentage of time spent in the open arms. 
Rotarod was used to assess motor coordination, motor learning, and stamina. Mice were 
placed on a 3 cm diameter rod with an initial rotation of 4 rpm and accelerated to 40 rpm over a 
maximum of 5 min (Ugo Basile, Italy). Mice were tested for latency to fall off the rod for four 
trials per day over two consecutive days. 
Wire hang test was used to measure subacute muscle function and fatigue. A horizontal 
wire (2 mm in diameter, 40 cm in length) was suspended above a padded table. The animal was 
allowed to cling in the middle of the wire with its forepaws for one 60 s trial, and latency to fall 
was recorded. 
Hind limb clasping was used as a marker for neurological dysfunction, including certain 
ataxias. The clasping test evaluated the animal’s hind limb response during tail suspension 10 cm 
above their home cage. If the hind limbs were consistently splayed outward, away from the 
abdomen, the mouse was assigned a score of 0. If one hind limb was retracted toward the abdomen, 
the animal received a score of 1. If both hind limbs were partially retracted toward the abdomen, 
it received a score of 2. The animal received a score of 3 if the animal’s hind limbs were entirely 
retracted and touching the abdomen. 
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The Y-maze spontaneous alternation task was used to test spatial working memory. Each 
animal was placed in a Y-maze and allowed to habituate to the maze environment for 5 minutes. 
The next day the mice were placed into the center of the maze and allowed to move freely through 
the maze for 5 minutes. Spontaneous alternation (entering all three arms sequentially without 
repetition) was calculated as follows: number of triads containing entries into all three 
arms/maximum possible alternations (the total number of arms entered – 2) x 100. Chance 
performance is 50%.  
 
Audiogenic Seizures 
For audiogenic seizure testing, mice were habituated to a sound attenuation chamber for 
60 sec and exposed to sound stimulation (115 dB) for 60 sec or until tonic-clonic episodes occurred 
(Ciarlone et al., 2016). An occurrence of sound-induced seizure was defined as tonic, clonic, or 
tonic-clonic seizures during sound stimulation. Animals were tested only once. Seizure testing was 
carried out between 1:00 PM and 6:00 PM to limit effects of diurnal variation on results. 
 
Pentylenetetrazol-Induced Seizures 
Pentylenetetrazol (PTZ, Sigma-Aldrich) dissolved in phosphate-buffered saline was 
injected intraperitoneally at a single convulsive dose of 60 mg/kg to test susceptibility to 
generalized convulsive seizures (Hill-Yardin et al., 2015). Animals were placed into chambers and 
monitored for 30 min after the injection. Behavioral responses were recorded using a video camera 
and seizure activity was classified according to the following scale (Ishisaka et al., 2013): 0) no 
abnormality; 1) exploring, sniffing, and grooming ceased, becoming motionless; 2) head-nodding, 
facial and forelimb clonus; 3) myoclonic jerks of the head and neck, with brief twitching 
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movements, or repetitive movements with head-bobbing or tail rigidity; 4) forelimb or forelimb 
and hind limb clonus, reciprocal forepaw padding, hind limb abduction, continuous rearing, and 
falling, Straub tail response; 5) tonic convulsions; 6) death. The highest seizure score was recorded 
during each minute, and total scores were calculated as the sum of the minute-by-minute scores.  
  
Extracellular Recordings 
Following behavioral testing, a cohort of mice was euthanized and the hippocampi 
dissected out to be used in hippocampal LTP experimentation as previously described (Trotter et 
al., 2013). The brain was rapidly dissected and placed in ice-cold, oxygenated cutting solution 
containing (in mM): 110 sucrose, 60 NaCl, 3 KCl, 28 NaHCO3, 1.25 NaH2PO4, 5 glucose, 0.6 
ascorbate, 7 MgCl2, and 0.5 CaCl2. Hippocampal slices (400 μm) were prepared on a vibratome 
and allowed to equilibrate in a 50% cutting saline and 50% artificial cerebrospinal fluid solution 
containing (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose, 1 MgCl2, and 2 
CaCl2. Slices were maintained in this solution with constant 95% O2/5% CO2 perfusion for 10 min 
before being transferred to the brain slice recording chamber supported by nylon mesh or 
maintained in a holding container. Slices were recovered for a minimum of 1 h before recording. 
The recording chamber was held at 30° ± 0.5°C with a ACSF flow rate of 1 ml/min. Field 
excitatory postsynaptic potentials (fEPSPs) were recorded from stratum radiatum in hippocampal 
area CA1 via glass microelectrodes filled with artificial cerebrospinal fluid (resistance 1–4 mΩ). 
Responses were generated by stimulation of Schaffer collaterals arising from the CA3 region. 
Stimulating electrodes consisted of formvar-coated nichrome wire, which was used to deliver 
biphasic stimulus pulses (1–15 V, 100 μs duration, 0.05 Hz). Delivery of stimulation, controlled 
by pClamp 9.0 software (Molecular Devices), was via the Digidata 1322A interface (Molecular 
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Devices) and a stimulus isolator (model 2200; A-M Systems). Signals were amplified using a 
differential amplifier (model 1800; A-M Systems), filtered at 1 kHz, and digitized at 10 kHz. For 
all experiments, baseline stimulus intensity was set at the level that elicited ∼50% of the maximum 
fEPSP response as determined from the input–output curve. The input–output relationship was 
determined by stimulating slices from 0 to 15 mV at 0.5 mV increments. Short-term plasticity was 
measured via paired-pulse facilitation (PPF), which was induced by stimulating slices at half-max 
intensity with sequential pulses spaced at 20 ms intervals from 20 to 300 ms. LTP was induced by 
a theta-burst stimulation (TB-stimulation) protocol, which consisted of five trains of four pulse 
bursts at 200 Hz separated by 200 ms, repeated six times with an intertrain interval of 10 s. For 
analysis, the last 10 minutes of recording was averaged and compared. 
 
Statistical Analysis 
All data is represented as the mean ± SEM. Data was analyzed using Student’s t-test or 
ANOVA followed by Tukey’s Multiple Comparison test, set at a significance of p < 0.05 
(GraphPad Prism software). 
 
Results 
Short-Term Ganaxolone Administration Decreases Anxiety and Improves Motor  
Deficits in AS Mice 
To evaluate general anxiety, percent time spent in the open arm of the EPM was analyzed 
by two-way ANOVA with genotype and treatment as factors. AS mice spent significantly less time 
in the open arm compared to WT controls and AS treated animals (Figure 3.1A). We found a 
 72 
 
significant interaction of group and treatment (F (1,42) = 5.20, p < 0.05; Bonferroni post-hoc tests: 
WT vs. AS p < 0.05, AS vs. AS GNX p < 0.05). 
Figure 3.1. Short-term ganaxolone administration significantly improves the anxiety motor, and 
audiogenic seizure phenotypes in the AS mouse similar to WT controls. (A) WT and AS mice were 
treated with BCD or GNX for 3 days and then tested in the EPM. Bars represent % total time spent 
in the open arms of the EPM during a 5 min test period. AS mice spent less time in the open arms 
than WT mice. GNX did not affect the open arm time of WT mice but GNX did increase the open 
time of AS mice so that it was not significantly different from that in WT mice (WT and WT GNX: 
n=12; AS and AS GNX: n=13). (B) Mice were tested on an accelerating rotarod for 4 trials a day 
for 2 days. AS mice exhibited a significantly reduced average latency to fall. GNX treatment did 
not affect average latency to fall values in WT animals. AS GNX animals did not perform 
significantly different from that of WT mice (WT and WT GNX: n=12; AS and AS GNX: n=13). 
(C) Latency to fall in the wire hang test was unaffected by GNX treatment compared to BCD-
treated controls. AS mice performed poorly on the wire hang task compared to WT controls. AS 
GNX mice demonstrated a significant increase in the latency to fall that was not significantly 
different from that of WT mice (WT: n=8; WT GNX and AS: n=6; AS GNX: n=4). (D) GNX-
treated AS mice exhibited a reduced frequency of audiogenic seizures following 115 dB sound 
stimulation compared with BCD-treated control mice. (E) Latency to seizure following audiogenic 
stimulation was significantly increased in AS GNX mice compared to BCD-treated controls (AS: 
n=19; AS GNX: n=16; *p < 0.05, **p<0.01, ***p < 0.001). 
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 Following the 3 day ganaxolone treatment, AS control mice demonstrated significant 
deficits in rotarod performance compared to WT controls and AS GNX-treated mice (Figure 3.1B, 
repeated measures ANOVA p < 0.001; WT and AS GNX vs. AS p < 0.001). AS mice also 
demonstrated a significant hind limb clasping phenotype compared to WT controls and AS treated 
mice (Figure 3.1C). A two-way ANOVA revealed a significant effect of genotype (F (1,17) = 8.66, 
p < 0.01; Bonferroni post-hoc tests: WT vs. AS p < 0.01; AS vs. AS GNX p < 0.05). All WT and 
WT GNX mice were able to hang for the maximum trial time of 60 seconds, while 20% of AS and 
75% of AS GNX mice reached the maximum trial duration. 
 
Short-Term Ganaxolone Treatment Decreases Audiogenic Seizure Frequency and  
Latency 
Following audiogenic stimulation, we observed seizures in 63% of the AS mice, whereas 
no seizures were observed in WT animals (data not shown). AS mice treated for 3 days with 
ganaxolone demonstrated a 45% reduction in seizure activity compared to AS controls when tested 
(Figure 3.1D, p < 0.05 Fisher’s exact test). AS treated animals also demonstrated a significant 
increase in latency to seize (50.94 sec) compared to AS controls (28.02 sec) (Figure 3.1E, p < 
0.01).  
 
Ganaxolone Decreases Anxiety and Improves Motor Coordination 
General locomotor activity was examined in the open field test, as measure by overall 
distance traveled in 15 minutes. There was no significant difference in general locomotion in mice 
treated with ganaxolone for four weeks (Figure 3.2A). Anxiety was measured in the elevated plus 
maze as percent time spent in the open arm of the maze. AS GNX mice spent significantly more 
time in the open arm compared to AS controls (Figure 3.2B). A two-way ANOVA revealed a 
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significant interaction of group and treatment (F (1,36) = 6.32, p < 0.05; Bonferroni post-hoc tests: 
AS vs. AS GNX p < 0.05). AS mice were more anxious than WT controls, similar to reports of 
patients with AS (Clayton‐Smith, 2001; Thibert et al., 2013). 
Figure 3.2. Chronic ganaxolone administration decreases anxiety and improves motor 
coordination in AS mice without affecting general locomotor activity. (A) Open field: distance 
traveled. Following 4 weeks of ganaxolone administration, mice underwent open-field testing as 
control for general locomotor activity. Data represent the overall distance traveled in the open 
field. There were no significant differences between experimental groups (WT and AS controls: 
n=12; WT GNX: n=10; AS GNX: n=11). (B) Elevated plus maze: anxiety levels were significantly 
decreased in AS GNX mice compared to AS controls (WT: n=13; AS: n=9; WT GNX: n=12; AS 
GNX: n=10). (C) Average latency to fall on the accelerating rotarod was significantly decreased 
in AS mice compared to WT controls, while AS treated mice demonstrated significant motor 
improvements compared to AS BCD mice (WT: n=13; AS: n=9; WT GNX: n=12; AS GNX: 
n=10). (D) Severity of the hind limb clasping score was significantly decreased in AS GNX-treated 
mice (WT and WT GNX: n=18; AS: n=16; AS GNX: n=17; *p < 0.05 and ***p < 0.001). 
  
Following 4 weeks of ganaxolone administration, we observed significantly improved 
motor coordination and motor learning in AS GNX mice compared to AS controls as demonstrated 
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by an increased latency to fall off the rotarod (Figure 3.2C, repeated measures ANOVA p < 0.0001; 
WT vs. AS and AS GNX p < 0.001; AS vs. AS GNX p < 0.001; WT vs. WT GNX p < 0.05). 
Neurological and motor improvement was also observed by a significantly decreased hind limb 
clasping score in AS treated mice compared to AS BCD animals (Figure 3.2D). A two-way 
ANOVA revealed a significant effect of genotype (F (1,63) = 65.84, p < 0.0001) and treatment (F 
(1,63) = 4.79, p < 0.05) (Bonferroni post-hoc tests: WT vs. AS p < 0.001; AS vs. AS GNX p < 
0.001; WT vs. WT GNX p < 0.05).  
 
Long-Term Ganaxolone Treatment Recovers Spatial Working Memory and LTP  
Deficits 
Figure 3.3. Effects of ganaxolone on spontaneous alternation behavior in the Y-maze task. (A) 
Percentage of spontaneous alternation in the Y-maze. AS mice displayed significant deficits in the 
Y-maze spontaneous alternation task compared to WT, WT GNX, and AS GNX mice. The dashed 
line represents the chance level of alternation (random, 50%). (B) The number of total entries in 
the arms of the Y-maze did not differ significantly between groups (n=8, *p < 0.05). 
 
Spontaneous alternation behavior, which is regarded as a measure of spatial working 
memory, was investigated next. AS mice displayed significantly impaired working memory when 
measured four weeks post osmotic pump implantation, whereas the AS GNX group performed to 
WT levels (Figure 3.3A). A two-way ANOVA revealed a significant interaction of group and 
treatment (F (1,26) = 6.32, p < 0.01; Bonferroni post-hoc tests: WT vs. AS p < 0.05; AS vs. AS 
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GNX p < 0.05). The total number of entries into the arms of the maze was not significantly different 
between all experimental groups, demonstrating that general locomotor activity was not affected 
by ganaxolone in this task (Figure 3.3B). 
Figure 3.4. Chronic ganaxolone treatment increases hippocampal LTP induction and 
maintenance without changes in synaptic transmission. (A) Input-output curves at hippocampal 
SC-CA1 synapses in WT, WT GNX, AS, and AS GNX-treated mice. There were no significant 
difference between experimental groups. (B) Short-term synaptic plasticity was evaluated by the 
amount of PPF with IPIs ranging from 20 to 300 ms. There were no significant differences between 
experimental groups. (C) Long-term potentiation induced by 5 trains of theta-burst stimulation 
(tbs; arrow). Representative traces are shown for all groups at baseline (black trace) and 50 minutes 
after tetanic stimulation (grey trace). Scale bar = 1 mV and 5 ms. (D) LTP induction calculated 
between 50 and 60 min after theta-burst stimulation. Data expressed as mean ± SEM. (WT = 21 
slices, n = 4 mice; WT GNX = 22 slices, n = 5 mice; AS = 16 slices, n = 4 mice; AS GNX = 13 
slices, n = 3 mice; p < 0.001). 
 
Using a TB-stimulation LTP protocol, the extent of LTP, calculated by averaging the slope 
values of fEPSPs recorded between 50 and 60 minutes after stimulation, was calculated. The level 
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of potentiation was significantly lower in slices from AS mice (92.1 ± 0.61) compared to those 
from WT animals (131.2 ± 1.06) (Figures 3.4C and 3.4D, ANOVA, Bonferroni post-hoc tests, p < 
0.001). Chronic ganaxolone treatment recovered the LTP impairment in area CA1 of AS GNX 
mice (Figures 3.4C and 3.4D, 125.6 ± 0.75, p < 0.001) compared to AS controls. There were no 
changes observed in baseline synaptic transmission (input-output relationship, Figure 3.4A) or 
short-term synaptic plasticity (paired-pulse facilitation, Figure 3.4B).  
 
Long-Term Ganaxolone Treatment Attenuates Seizure Activity 
Audiogenic seizures were observed in 67% of AS mice, while only 20% of AS mice treated 
with ganaxolone for 4 weeks exhibited audiogenic seizures (Figure 3.5A, p < 0.05 Fisher’s exact 
test). No seizures were observed in the WT group (data not shown). AS mice treated with 
ganaxolone for 4 weeks also demonstrated a significant increase in seizure latency (50.88 sec) 
compared to AS BCD mice (29.47 sec) (Figure 3.5B, p < 0.05). 
PTZ-induced seizure severity was significantly increased in AS BCD mice compared to 
WT controls and AS-treated mice (Figure 3.5C, repeated measures ANOVA p < 0.001). Total 
seizure scores for AS mice recorded during the 30-minute time period were also significantly 
higher than WT controls and AS GNX-treated mice, suggesting ganaxolone significantly reduces 
chemically-induced tonic-clonic seizure activity in AS mice (Figure 3.5D, p < 0.001). A two-way 
ANOVA revealed a significant effect of genotype (F (1,27) = 21.44, p < 0.0001) and treatment (F 
(1,27) = 10.94, p < 0.01), with a significant interaction of group and treatment (p < 0.01) 
(Bonferroni post-hoc tests: WT vs. AS p < 0.001; AS vs. AS GNX p < 0.001). These results are 
consistent with previous reports demonstrating that ganaxolone protects against chemically-
induced seizures (Gasior et al., 2000; Reddy and Rogawski, 2000). 
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Figure 3.5. Chronic ganaxolone administration attenuates enhanced seizure susceptibility of AS 
mice. (A) AS mice treated chronically with GNX for 4 weeks exhibited a reduced frequency of 
behavioral seizures in response to 115 dB sound stimulation compared with BCD vehicle treated 
control mice. (B) Latency to seizure following sound stimulation was significantly increased in 
AS GNX mice compared with BCD vehicle treated controls (AS: n=9; AS GNX: n=10; *p < 0.05). 
(C) AS mice were more susceptible to PTZ-induced seizures than AS GNX and WT control 
animals. Data points represent mean ± SEM of highest seizure score at successive 2 min intervals 
following PTZ treatment. (D) Total seizure scores of each animal. The highest total scores were 
recorded in AS control mice compared to WT controls and AS-treated mice (WT, WT GNX, and 
AS: n=8; AS GNX: n=7; *p < 0.001). 
 
 
 
Discussion 
 
One of the most devastating effects of reduced neuronal UBE3A in humans is seizure 
susceptibility, with >80% of individuals presenting with epilepsy of which approximately 70% are 
medically refractory (Thibert et al., 2012). Patients also commonly exhibit high levels of anxiety 
and motor-related disturbances such as tremor, which progress with age (Clayton‐Smith, 2001; 
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Pelc et al., 2008; Thibert et al., 2013). Both epilepsy and motor dysfunction may be attributed to 
imbalances in excitation and inhibition. Such imbalances, which are believed to result from 
diminished synaptic and extrasynaptic GABAA receptor mediated inhibition, have been 
documented in the cortex and cerebellum of the AS mouse (Egawa et al., 2012). Moreover, 
GABAergic dysfunction and the resulting circuit hyperexcitability may contribute to the impaired 
learning and memory associated with the disorder (Egawa et al., 2012; Judson et al., 2016; Wallace 
et al., 2012). In the present study, we investigated the potential of ganaxolone, a positive allosteric 
modulator of GABAA receptors, to reduce the enhanced seizure susceptibility and rescue the major 
behavioral and neurological defects in a mouse model of AS.  Ganaxolone is an attractive potential 
treatment agent because it is orally active and has a good safety record (Bialer et al., 2013). 
Ganaxolone modulates both synaptic and extrasynaptic GABAA receptors (Martinez Botella et al., 
2015). This distinguishes it from benzodiazepines, the positive GABAA receptor modulators most 
commonly used clinically, which only act on synaptic GABAA receptors. Moreover, in contrast to 
benzodiazepines that have a high propensity for tolerance, studies in animals have indicated that 
the anti-seizure activity of ganaxolone does not diminish with chronic treatment (Reddy and 
Rogawski, 2000). In addition, in clinical trials ganaxolone has been found to maintain efficacy in 
some patients for periods of years (Bialer et al., 2013). 
 Given the lack of tolerance in these prior studies, we surmised that the anti-seizure activity 
of ganaxolone in AS mice would not diminish following 4 week treatment when compared with 
the effect obtained after 3 days of treatment. However, there is only limited information on the 
extent to which there is tolerance to the other behavioral actions of ganaxolone, including the 
anxiolytic and motor related actions. Therefore, it was of interest to determine if such other effects 
of ganaxolone would be maintained with 4 week treatment. We initially evaluated the short-term 
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anticonvulsant, anxiolytic, and motor-related effects of ganaxolone in our seizure-prone AS mouse 
model. Previous studies have demonstrated anticonvulsant and anxiolytic effects of the drug in 
rodent models within 10 to 30 minutes after injection (Heulens et al., 2012; Kazdoba et al., 2016; 
Reddy and Rogawski, 2000). These latter effects may in part relate to increased tonic inhibition in 
the amygdala (Akwa et al., 1999; Romo-Parra et al., 2015). In the AS mice, 3 day ganaxolone 
treatment improved seizure susceptibility. Although anxiolytic and anti-seizure effects have 
previously been obtained with non-toxic doses of ganaxolone in mice and rats (Gasior et al., 1997; 
Mareš and Stehlíková, 2010), motor impairment occurs at only modestly greater doses 
(Hogenkamp et al., 2014). Therefore, we were concerned that ganaxolone might have untoward 
actions in AS mice, which have impairments in motor function throughout their lives, manifesting 
as gait ataxia, poor motor coordination and learning, and defective hind limb clasping (Egawa et 
al., 2012; Heck et al., 2008; Jiang et al., 1998; Meng et al., 2013; Van Woerden et al., 2007). 
However, these concerns were found to be unwarranted as ganaxolone did not degrade motor 
function in AS mice and, indeed, we were able to document improvements in the rotarod and wire 
hang task.  
 We also sought to determine if continuous, extended ganaxolone delivery for 4 weeks 
would provide maintained seizure protection in the AS mouse. Extended ganaxolone 
administration has been reported for up to 10 days (Reddy and Rogawski, 2000), but to our 
knowledge, chronic dosing for longer periods has not been studied in rodents. To avoid the stress 
and anxiety of multiple daily injections, we administered ganaxolone via osmotic mini-pumps 
implanted subcutaneously, which allow for continuous dosing and a constant plasma 
concentrations. After four weeks of continuous administration, we found that ganaxolone 
treatment resulted in similar anxiolytic, positive motor, and anticonvulsant effects as was obtained 
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with short-term treatment. Thus, in addition to the expected lack of tolerance to the anti-seizure 
efficacy of ganaxolone there was no tolerance to the other therapeutic actions in AS mice. To our 
knowledge, lack of tolerance to such other therapeutic actions of ganaxolone has not previously 
been demonstrated. 
 One of the most surprising effects of ganaxolone is the reversal of motor learning deficits 
in the AS mice, which we observed with both short- and long-term treatment. AS patients have 
fine and gross motor impairments that affect many other essential functions such as feeding, 
movement, and communication (Beckung et al., 2004; Clayton-Smith and Laan, 2003; Lossie et 
al., 2001). Therefore, if the improvement in motor coordination and motor learning obtained in AS 
mice translates to humans, ganaxolone could significantly improve quality-of-life in AS patients. 
Our demonstration of improved motor function in AS mice with ganaxolone is consistent with a 
previous study showing that gaboxadol enhances motor performance and normalizes Purkinje cell 
firing in the AS mice (Egawa et al., 2012). In contrast to ganaxolone, which is an allosteric 
modulator of both synaptic and extrasynaptic GABAA receptors, gaboxadol is an agonist that acts 
directly at the GABA recognition site of GABAA receptors and is highly selective for extrasynaptic 
receptors. There is no evidence that benzodiazepines, which are selective modulators of synaptic 
GABAA receptors, produce motor improvement in AS. Therefore, it seems likely that the improved 
motor performance induced by ganaxolone is predominantly a result of its actions on extrasynaptic 
GABAA receptors. 
 An excitatory/inhibitory imbalance has been established in the AS cortex, along with 
decreased cerebellar tonic inhibition and Ube3a loss in cortical GABAergic neurons (Egawa et al., 
2012; Judson et al., 2016; Wallace et al., 2012). These alterations can lead to circuit 
hyperexcitability and defective sensory integration, detection, and processing, and may be linked 
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to the phenotypic deficits we observe in AS. Previous work has also demonstrated that inhibition 
of hilar GABAergic interneuron activity impairs spatial learning and memory, and learning ability 
relies on increased inhibitory synaptic plasticity and GABA release (Andrews-Zwilling et al., 
2012; Cui et al., 2008). It has also been suggested that the balance of excitatory and inhibitory 
neuronal activity in the hippocampus is critical for synaptic plasticity and normal learning (Cui et 
al., 2008). Therefore, one potential explanation for the action of ganaxolone in AS is that a 
synthetic neurosteroid analog that functions as a GABAA positive allosteric modulator may 
increase the neuronal signal-to-noise ratio, resulting in enhanced information processing and 
potential learning and memory improvement. Interestingly, we found that ganaxolone rescues both 
the spatial working memory and hippocampal synaptic plasticity deficits in AS mice, while 
decreasing LTP in WT treated animals. The contrasting electrophysiological results observed in 
WT mice were not unexpected, given that progesterone, the precursor of allopregnanolone, 
decreases LTP in rat CA1 neurons (Foy et al., 2008), and increased tonic inhibition could alter 
synaptic plasticity. However, the way in which ganaxolone ameliorates learning and memory 
deficits in the AS mouse remains to be determined. 
 Extensive experience in human clinical trials has shown ganaxolone to be well tolerated 
and safe. Moreover, several oral dosage forms (suspension and capsule) are available that allow 
ganaxolone to be administered conveniently to children and adults. Ganaxolone is not currently 
approved for any clinical indication, although human studies in various conditions are ongoing. 
Our present results indicate that ganaxolone might be particularly well suited as a symptomatic 
treatment for AS, with the potential to not only treat the seizures but also to provide long-lasting 
improvement in the diverse neurobehavioral and motor symptoms. Children with AS are at risk of 
early death due to poorly controlled epilepsy (Ruggieri and McShane, 1998), and therefore it is of 
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interest to determine if ganaxolone can protect against seizures in AS as we have shown is the case 
in the mouse model. Consequently, clinical trials are warranted. In addition, our results are 
consistent with other work (Roden et al., 2010), suggesting that positive modulators of 
extrasynaptic GABAA receptors might in general provide unique symptomatic benefits in AS. 
Investigation of other extrasynaptic GABAA receptors’ active agents including gaboxadol will be 
of interest. 
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CHAPTER FOUR: 
 
DISCUSSION3 
 
Future Directions 
 Our work utilizing a ketone ester in the Angelman syndrome mouse model revealed 
significant alterations in hippocampal amino acid metabolism. We reported upregulation of 
GAD65/67 expression and increased [GABA/glutamate], which supports the enhanced 
GABAergic inhibition hypothesis. However, it is unlikely the observed improvements in AS mice 
administered the KE are the result of solely one mechanism. Future work should explore the energy 
production hypothesis, with alterations in mitochondrial biogenesis as a primary focus. 
Mitochondrial dysfunction has been reported in the hippocampal CA1 of AS mice. These 
neurons display small, dense mitochondria compared to controls, with structural cristae 
abnormalities and a partial oxidative phosphorylation defect at complex III in the whole brain (Su 
et al., 2011a). Recent work has also demonstrated enhanced levels of mitochondrial superoxide in 
the AS mouse hippocampus, which was reduced by MitoQ, a mitochondria-targeted antioxidant 
that readily crosses the blood-brain barrier. MitoQ treatment also rescued LTP and fear 
conditioning deficits, suggesting enhanced mitochondrial ROS production may contribute to 
hippocampal pathophysiology in AS mice (Santini et al., 2015). Moreover, improvements in motor 
coordination and anxiety in AS animals have been observed following treatment with idebenone, 
                                                 
3 Portions of this chapter have been previously published in Expert Opinion on Orphan Drugs, 2016, 4(3): 317-325, 
and have been reproduced with permission from Taylor & Francis. See Appendix B. 
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a CoQ10 analogue, which restores electron flow to the mitochondrial respiratory chain and 
increases mitochondrial antioxidant capacity (Llewellyn et al., 2015). 
Ketones preserve hippocampal CA1 synaptic function induced by mitochondrial 
respiration inhibitors (Kim et al., 2010), likely through an antioxidant mechanism or via increased 
ATP production. Moreover, ketone bodies diminish ROS production by increasing NADH 
oxidation in dissociated neocortical neurons and isolated neocortical mitochondria (Maalouf et al., 
2007). This data suggests a ketone ester could demonstrate significant neuroprotective effects via 
alterations in energy metabolism and attenuated oxidative stress. However, it remains to be 
determined if BD-AcAc2 exhibits improvements in the same capacity as the aforementioned 
therapeutics. Mitochondrial ROS production, complex activity, protein levels, and structure should 
be examined prior to and following KE supplementation in AS mice.   
 The neuronal glutamatergic/GABAergic imbalance is frequently described in mouse 
models of autism (Gogolla et al., 2009) and AS (Egawa et al., 2012; Judson et al., 2016; Wallace 
et al., 2012). This underlying circuit defect may account for many of the behavioral phenotypes 
typically reported in autism and autism-related disorders. Interestingly, GABA and glutamate 
signaling abnormalities may also be associated with inflammatory pathways in the autistic brain 
(El-Ansary and Al-Ayadhi, 2014). Neuroinflammation has been hypothesized to play a significant 
role in both autism (Alabdali et al., 2014; Vargas et al., 2005; Wang et al., 2014) and the epileptic 
brain, which suggests it likely plays a prominent role in AS as well. The ketogenic diet decreases 
peripheral inflammation in both juvenile and adult rats (Ruskin et al., 2009), and also mitigates 
MPTP-induced neurotoxicity and microglial activation (Yang and Cheng, 2010). Moreover, BHB 
demonstrates anti-inflammatory properties due to NLRP3 inflammasome inhibition (Youm et al., 
2015) and suppression of ER stress indicators (Bae et al., 2016). Preliminary data following KE 
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administration in AS mice provides similar results, manifested as a significant increase in latency 
to hind paw response on the hot plate task in AS KE mice (data not shown). This indicates KE 
administration and its effects on peripheral inflammation should be further explored in AS and 
other rodent models. Chronic KE supplementation alters the serum inflammatory profile, and 
decreases pro-inflammatory cytokines such IL-1β, IL-6, IFN-γ, MCP-1, and RANTES. VEGF, an 
anti-inflammatory cytokine, is  significantly increased following chronic KE administration  
(Weeber et al., 2016). Additionally, the neurosteroid allopregnanolone has also demonstrated anti-
inflammatory properties, attenuating production of pro-inflammatory cytokines following brain 
trauma (He et al., 2004) and in multiple sclerosis (Noorbakhsh et al., 2011). More specifically, 
ganaxolone, the synthetic analog of allopregnanolone, alters GABA transport via downregulation 
of GAT-2, which also has downstream transcriptional involvement with neuroinflammatory genes 
(Paul et al., 2014). 
While it is likely neuroinflammation plays a significant role in AS, at least in regard to the 
epilepsy phenotype, published work has yet to thoroughly evaluate this mechanism. However, one 
publication did report a significant downregulation of melanocortin receptor 1 (Mc1r) at the 
transcriptional and protein level in the AS mouse brain. Mc1r prevents brain inflammation and 
provides a neuroprotective effect via a reduced production and inhibition of many pro-
inflammatory agents. It remains to be determined if AS mice or humans have a significantly altered 
inflammatory profile, and if KE supplementation or ganaxolone administration could have a 
positive effect. 
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Concluding Remarks 
Generally, with the implementation of several disparate lines of research focused on 
potential therapeutic targets for AS, specific correlations of the reported data in the context of four 
major phenotypes (motor learning and coordination, seizure, learning and memory, and synaptic 
plasticity) can be made. For example, rescue of the hippocampal synaptic plasticity phenotype is 
typically associated with the rescue of the learning and memory phenotype. One possible 
explanation for this may be seen in the parameters of the synaptic plasticity defect in the AS mouse. 
The AS mouse hippocampal LTP defect is overcome with multiple trains of high-frequency 
stimulation (Weeber et al., 2003), suggesting an increased threshold to synaptic plasticity exists, 
at least in the synapses of area CA1 of the hippocampus. Thus, application of modulators or 
activators of synaptic plasticity, such as GABAA receptor modulators, successfully lower this 
threshold allowing a more normalized synaptic function and subsequent capacity for plasticity. 
This, in turn, results in the rescue of the learning and memory phenotype. Furthermore, the 
hippocampus and surrounding entorhinal cortex may underlie the learning and memory defect as 
demonstrated by the AAV-Ube3a studies showing expression in these specific areas, improvement 
in early-phase LTP, and an associated recovery of the hidden-platform water maze and fear 
conditioning defects (Daily et al., 2011).  
Seizure activity in the animal model for AS is considerably under-researched, especially in 
light of prominent epileptiform activity and often difficult to control seizures seen in the AS patient 
population (Laan et al., 1997; Pelc et al., 2008; Thibert et al., 2009). There may be multiple reasons 
for this trend; however, the most likely issue is that the C57BL/6 mouse strain and F1 hybrid 
generation (C57BL/6–129/SvEv) are most often used when behavioral assessment is involved. 
This is for the simple rationale that the C57BL/6 strain is easier to train in the hidden platform 
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water maze and has become the strain of choice for assessing cognitive disruption in other murine 
models (Crawley, 2008; Crusio, 2013). It should be noted that for this study, we did not record 
significant deficits in the performance of AS mice in the hidden platform water maze task (data 
not shown). Furthermore, the established literature on mouse behavior dictates that the C57BL/6 
strain be used for comparisons to other studies. It has been shown that differences in these two 
backgrounds can play a significant role in the behavior of the AS model (Huang et al., 2013). In 
the context of epilepsy research, the audiogenic seizure phenotype is greatly reduced in the F1 
generation AS mouse model and is non-existent in the C57BL/6 pure background. The C57BL/6 
background is also known to be seizure resistant to kainate compared to other pure background 
strains (McLin and Steward, 2006; Schauwecker, 2000). Thus, it was imperative in this study to 
measure seizure activity following treatment of the ketone ester or ganaxolone, but careful 
evaluation was necessary in both strains due to potentially conflicting results. However, this work 
demonstrated successful therapeutic use and similar results in both strains were observed in 
audiogenic (129/SvEv mice) and chemically-induced (129/SvEv and C57BL/6) seizure testing. 
Finally, like the seizure phenotype, the motor coordination defect appears to be another 
phenotype that is not rescued as often. This is not due to strain differences; however, similar to 
seizure in the AS mouse model, the molecular mechanisms and specific CNS regions underlying 
the balance and motor coordination phenotype is unclear. A recent report by Elgersma and 
colleagues using the cerebellar-specific vestibulo-ocular reflex (VOR) paradigm shows near-
normal function of the cerebellum (Bruinsma et al., 2015). This observation is in contrast to reports 
on abnormal mTOR signaling in the cerebellum of the AS mouse model (Sun et al., 2015) and 
atypical Purkinje cell firing rate and rhythmicity in AS mice (Chéron et al., 2005). There may be 
multiple sites of dysfunction or the defect in synaptic function extends beyond the hippocampus 
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to cortical-cerebellum communication. This possibility has been previously proposed (Cheron et 
al., 2014) and is consistent with the predictive model of global synaptic alteration.  
The exon 2 Ube3a null mutation Angelman syndrome mouse model has been at the center 
of AS research for well over a decade. Despite the strain-dependent influences on the phenotype, 
the consistency of a single model has allowed inter-laboratory comparisons of multiple areas of 
research. However, the increasing number of genetic, biochemical and pharmacological methods 
to rescue the major AS mouse model phenotypes suggests that additional models using more 
complex mammalian systems such as a rat, pig, or nonhuman primate models may be necessary 
for a refinement of existing and future potential translational therapeutics.                                                                                                                                    
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